<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id>
<journal-id journal-id-type="publisher-id">ijms</journal-id>
<journal-title-group>
<journal-title>International Journal of Molecular Sciences</journal-title>
</journal-title-group>
<issn pub-type="epub">1422-0067</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32575683</article-id>
<article-id pub-id-type="pmc">7352421</article-id>
<article-id pub-id-type="doi">10.3390/ijms21124391</article-id>
<article-id pub-id-type="publisher-id">ijms-21-04391</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS): Pathophysiology and Clinical Implications</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4879-4896</contrib-id>
<name>
<surname>Cabal-Herrera</surname>
<given-names>Ana Maria</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-21-04391">1</xref>
<xref ref-type="aff" rid="af2-ijms-21-04391">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9888-0565</contrib-id>
<name>
<surname>Tassanakijpanich</surname>
<given-names>Nattaporn</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-21-04391">1</xref>
<xref ref-type="aff" rid="af3-ijms-21-04391">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2412-9146</contrib-id>
<name>
<surname>Salcedo-Arellano</surname>
<given-names>Maria Jimena</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-21-04391">1</xref>
<xref ref-type="aff" rid="af4-ijms-21-04391">4</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5029-8448</contrib-id>
<name>
<surname>Hagerman</surname>
<given-names>Randi J.</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-21-04391">1</xref>
<xref ref-type="aff" rid="af4-ijms-21-04391">4</xref>
<xref ref-type="corresp" rid="c1-ijms-21-04391">*</xref>
</contrib>
</contrib-group>
<aff id="af1-ijms-21-04391"><label>1</label>UC Davis MIND Institute, UC Davis Health, Sacramento, CA 95817, USA; <email>ana.cabal@correounivalle.edu.co</email> (A.M.C.-H.); <email>tnattaporn.ped@gmail.com</email> (N.T.); <email>mjsalcedo@ucdavis.edu</email> (M.J.S.-A.)</aff>
<aff id="af2-ijms-21-04391"><label>2</label>Group on Congenital Malformations and Dysmorphology, Faculty of Health, Universidad del Valle, Cali, Valle del Cauca 760041, Colombia</aff>
<aff id="af3-ijms-21-04391"><label>3</label>Department of Pediatrics, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand</aff>
<aff id="af4-ijms-21-04391"><label>4</label>Department of Pediatrics, University of California, Davis, School of Medicine, Sacramento, CA 95817, USA</aff>
<author-notes>
<corresp id="c1-ijms-21-04391"><label>*</label>Correspondence: <email>rjhagerman@ucdavis.edu</email>; Tel.: +1-916-703-0247; Fax: +1-916-703-0240</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>20</day>
<month>6</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<month>6</month>
<year>2020</year>
</pub-date>
<volume>21</volume>
<issue>12</issue>
<elocation-id>4391</elocation-id>
<history>
<date date-type="received">
<day>20</day>
<month>4</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>5</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 by the authors.</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>The fragile X-associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative disorder seen in older premutation (55–200 CGG repeats) carriers of <italic>FMR1.</italic> The premutation has excessive levels of <italic>FMR1</italic> mRNA that lead to toxicity and mitochondrial dysfunction. The clinical features usually begin in the 60 s with an action or intention tremor followed by cerebellar ataxia, although 20% have only ataxia. MRI features include brain atrophy and white matter disease, especially in the middle cerebellar peduncles, periventricular areas, and splenium of the corpus callosum. Neurocognitive problems include memory and executive function deficits, although 50% of males can develop dementia. Females can be less affected by FXTAS because of a second X chromosome that does not carry the premutation. Approximately 40% of males and 16% of female carriers develop FXTAS. Since the premutation can occur in less than 1 in 200 women and 1 in 400 men, the FXTAS diagnosis should be considered in patients that present with tremor, ataxia, parkinsonian symptoms, neuropathy, and psychiatric problems. If a family history of a fragile X mutation is known, then <italic>FMR1</italic> DNA testing is essential in patients with these symptoms.</p>
</abstract>
<kwd-group>
<kwd>fragile X-associated tremor/ataxia syndrome (FXTAS)</kwd>
<kwd>
<italic>FMR1</italic>
</kwd>
<kwd>premutation</kwd>
<kwd>FMRP</kwd>
<kwd>ataxia</kwd>
<kwd>tremor</kwd>
<kwd>neuroradiology</kwd>
<kwd>neurodegeneration</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-ijms-21-04391">
<title>1. Fragile X Syndrome and Associated Disorders</title>
<p>Fragile X syndrome (FXS) is the most common cause of inherited intellectual disability and autism spectrum disorder (ASD). It results from the expansion of the CGG trinucleotide repeats (&gt;200) in the promoter region of the fragile X mental retardation 1 (<italic>FMR1</italic>) gene, located at Xq27.3 [<xref ref-type="bibr" rid="B1-ijms-21-04391">1</xref>]. The expansion leads to methylation and subsequent silencing of the gene. In some rare cases, less than 1%, FXS occurs due to other defects that lead to loss of function of the gene, such as deletions or point mutations [<xref ref-type="bibr" rid="B2-ijms-21-04391">2</xref>,<xref ref-type="bibr" rid="B3-ijms-21-04391">3</xref>]. The <italic>FMR1</italic> gene normally codes for the fragile X mental retardation protein (FMRP) and therefore silencing of the gene leads to loss of expression of the protein. FMRP is an RNA binding protein that is involved in several processes including neuronal plasticity and functioning of neuronal networks [<xref ref-type="bibr" rid="B4-ijms-21-04391">4</xref>,<xref ref-type="bibr" rid="B5-ijms-21-04391">5</xref>,<xref ref-type="bibr" rid="B6-ijms-21-04391">6</xref>]. Healthy individuals have less than 45 CGG repeats. Expansion to 46–54 repeats is considered the gray zone and individuals with 55–200 repeats are considered to have the premutation (PM) [<xref ref-type="bibr" rid="B7-ijms-21-04391">7</xref>]. Carriers of the PM can present with conditions such as fragile X-associated primary ovarian insufficiency (FXPOI) in females [<xref ref-type="bibr" rid="B8-ijms-21-04391">8</xref>], neuropsychiatric conditions such as anxiety and depression, recently recognized as fragile X-associated neuropsychiatric disorders (FXAND) [<xref ref-type="bibr" rid="B9-ijms-21-04391">9</xref>] and fragile X-associated tremor/ataxia syndrome (FXTAS) [<xref ref-type="bibr" rid="B10-ijms-21-04391">10</xref>]. In this review we will focus on FXTAS, a movement disorder characterized by tremor and/or ataxia, cognitive involvement, neuropathy, and autonomic dysfunction in individuals with the PM.</p>
<p>FXTAS was first described in 2001 by Hagerman and colleagues [<xref ref-type="bibr" rid="B11-ijms-21-04391">11</xref>] when they reported five elderly males who were carriers of the PM and presented with a progressive intention tremor, difficulty with ambulation, deficits in executive function and brain atrophy in association with elevated <italic>FMR1</italic> messenger RNA (mRNA) levels. Since then, FXTAS has become a well-known progressive neurodegenerative disorder that occurs in PM carriers, both men and women who are aging and present clinically with the core features of intention tremor and/or ataxia [<xref ref-type="bibr" rid="B12-ijms-21-04391">12</xref>]. There have been reports of individuals with CGG repeat numbers in the gray zone range presenting with clinical and neuroradiological findings consistent with FXTAS [<xref ref-type="bibr" rid="B13-ijms-21-04391">13</xref>,<xref ref-type="bibr" rid="B14-ijms-21-04391">14</xref>]. Although rare, there have also been reports of individuals with the full mutation (FM) who present with a clinical picture consistent with FXTAS. These individuals with the FM present with size mosaicism and/or lack of methylation of the <italic>FMR1</italic> gene and therefore have elevated mRNA levels and some production of FMRP [<xref ref-type="bibr" rid="B15-ijms-21-04391">15</xref>,<xref ref-type="bibr" rid="B16-ijms-21-04391">16</xref>,<xref ref-type="bibr" rid="B17-ijms-21-04391">17</xref>]. These cases have made experts consider modifications of clinical criteria for diagnosing FXTAS to not only involve premutation carriers but also those with a gray zone or FM repeat number [<xref ref-type="bibr" rid="B18-ijms-21-04391">18</xref>].</p>
<p>It is important for physicians to be aware of the PM and its associated disorders since it is likely they will encounter a patient with the PM in their clinic, and if they are unaware of their carrier status, they can misdiagnose conditions such as FXPOI or FXAND in addition to FXTAS. A meta-analysis conducted by Hunter and colleagues in 2014 determined that the prevalence of the PM in the general population is approximately 1 in 300 females and 1 in 850 males [<xref ref-type="bibr" rid="B19-ijms-21-04391">19</xref>]. It is noteworthy that the prevalence varies greatly globally with some countries reporting regions with prevalence as high as 1 in 28 females and 1 in 71 males [<xref ref-type="bibr" rid="B20-ijms-21-04391">20</xref>] and with Japan being the country with the lowest reported prevalence of the PM allele [<xref ref-type="bibr" rid="B21-ijms-21-04391">21</xref>].</p>
</sec>
<sec id="sec2-ijms-21-04391">
<title>2. Epidemiology of FXTAS</title>
<p>The only prevalence study of FXTAS among the premutation population was a total ascertainment study of all known fragile X families in California [<xref ref-type="bibr" rid="B22-ijms-21-04391">22</xref>]. They found that age was associated with an increased prevalence of tremor and ataxia in male carriers such that those in their 50s had a prevalence of 17% but those in their 80s had a prevalence of 75%. However, there are no prevalence studies in the general population [<xref ref-type="bibr" rid="B12-ijms-21-04391">12</xref>]. Many studies have addressed the premutation prevalence in patients presenting with movement disorders [<xref ref-type="bibr" rid="B23-ijms-21-04391">23</xref>] such as screening studies in adult patients presenting with ataxia [<xref ref-type="bibr" rid="B24-ijms-21-04391">24</xref>,<xref ref-type="bibr" rid="B25-ijms-21-04391">25</xref>], spinocerebellar ataxia [<xref ref-type="bibr" rid="B26-ijms-21-04391">26</xref>], multiple system atrophy [<xref ref-type="bibr" rid="B27-ijms-21-04391">27</xref>,<xref ref-type="bibr" rid="B28-ijms-21-04391">28</xref>,<xref ref-type="bibr" rid="B29-ijms-21-04391">29</xref>], parkinsonism [<xref ref-type="bibr" rid="B30-ijms-21-04391">30</xref>,<xref ref-type="bibr" rid="B31-ijms-21-04391">31</xref>,<xref ref-type="bibr" rid="B32-ijms-21-04391">32</xref>] and essential tremor [<xref ref-type="bibr" rid="B33-ijms-21-04391">33</xref>,<xref ref-type="bibr" rid="B34-ijms-21-04391">34</xref>,<xref ref-type="bibr" rid="B35-ijms-21-04391">35</xref>]. Overall, the prevalence of <italic>FMR1</italic> expansions in populations being evaluated for movement disorders is low (&lt;2%) but this could be explained by several factors such as lack of insight of patients with FXTAS into their symptoms resulting in them not reporting their neurological symptoms [<xref ref-type="bibr" rid="B36-ijms-21-04391">36</xref>] and the fact that few patients with FXTAS are being referred to and evaluated by a movement disorder specialist [<xref ref-type="bibr" rid="B37-ijms-21-04391">37</xref>]. Most of these studies concluded that due to the low prevalence of <italic>FMR1</italic> expansions in the populations studied, genetic testing should only be done if there are additional clinical features of fragile X- associated disorders or family history of fragile X disorders.</p>
<p>FXTAS is an age-dependent neurodegenerative disorder with prevalence increasing with age and affecting most commonly males [<xref ref-type="bibr" rid="B38-ijms-21-04391">38</xref>]. It is estimated that approximately over 40% of males with the PM will eventually present FXTAS [<xref ref-type="bibr" rid="B22-ijms-21-04391">22</xref>] in contrast with female carriers in whom it is estimated that approximately 13% to 16% of them will be affected by FXTAS [<xref ref-type="bibr" rid="B39-ijms-21-04391">39</xref>]. Other studies have shown that the penetrance may be also related to the CGG repeat size with lower repeats associated with lower penetrance [<xref ref-type="bibr" rid="B22-ijms-21-04391">22</xref>,<xref ref-type="bibr" rid="B40-ijms-21-04391">40</xref>,<xref ref-type="bibr" rid="B41-ijms-21-04391">41</xref>]. In the largest retrospective study of FXTAS to date, 55 men were included and the average age of symptom onset was 60.6 years (+/−8.6 years) [<xref ref-type="bibr" rid="B42-ijms-21-04391">42</xref>]. There are some reports of patients presenting with early onset of FXTAS in which they have had an environmental exposure that may have contributed to the earlier presentation and increased severity of symptoms; such as exposure to neurotoxins [<xref ref-type="bibr" rid="B43-ijms-21-04391">43</xref>], pollution, illicit drugs, pesticides, and alcohol consumption [<xref ref-type="bibr" rid="B44-ijms-21-04391">44</xref>,<xref ref-type="bibr" rid="B45-ijms-21-04391">45</xref>,<xref ref-type="bibr" rid="B46-ijms-21-04391">46</xref>]. The progression of FXTAS varies greatly among individuals and the life expectancy after symptoms onset has been established to be between 5 to 25 years with a median of 21 years [<xref ref-type="bibr" rid="B42-ijms-21-04391">42</xref>].</p>
</sec>
<sec id="sec3-ijms-21-04391">
<title>3. Clinical Presentation of FXTAS</title>
<p>The core presenting features of FXTAS are intention tremor and cerebellar ataxia. These usually present at a mean age of 62 with an action or intention tremor followed by the development of an ataxic gait; although 20% of patients have only ataxia [<xref ref-type="bibr" rid="B18-ijms-21-04391">18</xref>]. Neuropathy, parkinsonism, and executive dysfunction are commonly associated with FXTAS [<xref ref-type="bibr" rid="B47-ijms-21-04391">47</xref>]. In addition, several conditions are prevalent in PM carriers with and without FXTAS which include dysautonomia [<xref ref-type="bibr" rid="B18-ijms-21-04391">18</xref>,<xref ref-type="bibr" rid="B48-ijms-21-04391">48</xref>,<xref ref-type="bibr" rid="B49-ijms-21-04391">49</xref>,<xref ref-type="bibr" rid="B50-ijms-21-04391">50</xref>,<xref ref-type="bibr" rid="B51-ijms-21-04391">51</xref>], sleep problems [<xref ref-type="bibr" rid="B52-ijms-21-04391">52</xref>,<xref ref-type="bibr" rid="B53-ijms-21-04391">53</xref>], migraine headaches [<xref ref-type="bibr" rid="B54-ijms-21-04391">54</xref>], vestibular dysfunction [<xref ref-type="bibr" rid="B55-ijms-21-04391">55</xref>], hearing deficit [<xref ref-type="bibr" rid="B56-ijms-21-04391">56</xref>], olfactory deficit [<xref ref-type="bibr" rid="B57-ijms-21-04391">57</xref>], chronic fatigue [<xref ref-type="bibr" rid="B58-ijms-21-04391">58</xref>], and psychiatric problems [<xref ref-type="bibr" rid="B9-ijms-21-04391">9</xref>,<xref ref-type="bibr" rid="B59-ijms-21-04391">59</xref>,<xref ref-type="bibr" rid="B60-ijms-21-04391">60</xref>,<xref ref-type="bibr" rid="B61-ijms-21-04391">61</xref>,<xref ref-type="bibr" rid="B62-ijms-21-04391">62</xref>]. Fibromyalgia [<xref ref-type="bibr" rid="B51-ijms-21-04391">51</xref>,<xref ref-type="bibr" rid="B63-ijms-21-04391">63</xref>], autoimmune disorders [<xref ref-type="bibr" rid="B64-ijms-21-04391">64</xref>], and thyroid dysfunction [<xref ref-type="bibr" rid="B51-ijms-21-04391">51</xref>] are common in females with FXTAS. <xref ref-type="fig" rid="ijms-21-04391-f001">Figure 1</xref> illustrates the typical clinical progression of FXTAS.</p>
<p>Clinical presentation, age of onset, and severity of FXTAS are heterogeneous. A larger CGG repeat size in PM carriers predicts earlier age of onset and perhaps earlier death [<xref ref-type="bibr" rid="B40-ijms-21-04391">40</xref>,<xref ref-type="bibr" rid="B41-ijms-21-04391">41</xref>,<xref ref-type="bibr" rid="B65-ijms-21-04391">65</xref>]. Symptoms in females are milder since they have two X chromosomes [<xref ref-type="bibr" rid="B39-ijms-21-04391">39</xref>,<xref ref-type="bibr" rid="B66-ijms-21-04391">66</xref>]. The first five females with FXTAS reported did not have dementia [<xref ref-type="bibr" rid="B66-ijms-21-04391">66</xref>] but subsequent reports have included female cases of FXTAS with dementia [<xref ref-type="bibr" rid="B66-ijms-21-04391">66</xref>,<xref ref-type="bibr" rid="B67-ijms-21-04391">67</xref>]. Increasing X-inactivation ratio and skewed inactivation of the mutated allele in females can be a protective factor [<xref ref-type="bibr" rid="B66-ijms-21-04391">66</xref>,<xref ref-type="bibr" rid="B68-ijms-21-04391">68</xref>,<xref ref-type="bibr" rid="B69-ijms-21-04391">69</xref>]. Lower AGG interruptions and elevated expression of <italic>antisense FMR1</italic> transcript/splice variant 2 (<italic>ASFMR1</italic>-TV2) might predict the development of FXTAS [<xref ref-type="bibr" rid="B70-ijms-21-04391">70</xref>]. Moreover, the onset and progression of FXTAS might be accelerated if the PM carriers have a history of exposure to toxic substances. A dramatic decline in neurocognitive and neuromotor function after unrelated-FXTAS surgery requiring general anesthesia [<xref ref-type="bibr" rid="B43-ijms-21-04391">43</xref>,<xref ref-type="bibr" rid="B71-ijms-21-04391">71</xref>], chemotherapy for breast cancer [<xref ref-type="bibr" rid="B72-ijms-21-04391">72</xref>], exposure to chemical agents including insecticides, pesticides, herbicides, and chemicals for building [<xref ref-type="bibr" rid="B43-ijms-21-04391">43</xref>], and chronic substance use [<xref ref-type="bibr" rid="B45-ijms-21-04391">45</xref>,<xref ref-type="bibr" rid="B73-ijms-21-04391">73</xref>,<xref ref-type="bibr" rid="B74-ijms-21-04391">74</xref>] have been reported.</p>
<sec id="sec3dot1-ijms-21-04391">
<title>3.1. Tremor</title>
<p>The peak age of onset of tremor in males with the PM is usually in their early 60s [<xref ref-type="bibr" rid="B41-ijms-21-04391">41</xref>,<xref ref-type="bibr" rid="B42-ijms-21-04391">42</xref>], approximately 2 years prior to the onset of ataxia [<xref ref-type="bibr" rid="B42-ijms-21-04391">42</xref>]. The tremor is typically an action or intention tremor but may also be present with holding a position [<xref ref-type="bibr" rid="B56-ijms-21-04391">56</xref>,<xref ref-type="bibr" rid="B76-ijms-21-04391">76</xref>]. Almost half of the patients do not notice their tremor although it can be seen with writing, drinking, and eating [<xref ref-type="bibr" rid="B18-ijms-21-04391">18</xref>]. Head tremor, titubation, and voice tremor are found in 10% of patients with FXTAS [<xref ref-type="bibr" rid="B56-ijms-21-04391">56</xref>]. Resting tremor occurs in 13–26% of individuals with FXTAS and it typically co-occurs with other types of tremor [<xref ref-type="bibr" rid="B56-ijms-21-04391">56</xref>,<xref ref-type="bibr" rid="B76-ijms-21-04391">76</xref>,<xref ref-type="bibr" rid="B77-ijms-21-04391">77</xref>].</p>
</sec>
<sec id="sec3dot2-ijms-21-04391">
<title>3.2. Cerebellar Gait Ataxia</title>
<p>The average age of onset of ataxia is 63.6 ± 7.3 years [<xref ref-type="bibr" rid="B41-ijms-21-04391">41</xref>]. Cognitive function is also often impaired when ataxia is detected [<xref ref-type="bibr" rid="B56-ijms-21-04391">56</xref>]. Difficulty in performing tandem gait, taking a longer time to turn, and increased gait variability are the initial signs of ataxia [<xref ref-type="bibr" rid="B56-ijms-21-04391">56</xref>,<xref ref-type="bibr" rid="B78-ijms-21-04391">78</xref>]. These lead to gait instability and falling [<xref ref-type="bibr" rid="B18-ijms-21-04391">18</xref>,<xref ref-type="bibr" rid="B42-ijms-21-04391">42</xref>]. Dysmetria and dysarthria are commonly noted on examination [<xref ref-type="bibr" rid="B18-ijms-21-04391">18</xref>].</p>
</sec>
<sec id="sec3dot3-ijms-21-04391">
<title>3.3. Neuropathy</title>
<p>Around 80% of individuals with FXTAS have peripheral neuropathy, although it is underrecognized by patients [<xref ref-type="bibr" rid="B76-ijms-21-04391">76</xref>]. Neuropathy usually presents before motor symptoms of FXTAS develop [<xref ref-type="bibr" rid="B12-ijms-21-04391">12</xref>] and it can be the presenting symptom of FXTAS [<xref ref-type="bibr" rid="B79-ijms-21-04391">79</xref>]. Numbness and neuropathic pain are typical; impaired vibration sense and abnormal deep tendon reflexes are usually detected [<xref ref-type="bibr" rid="B76-ijms-21-04391">76</xref>,<xref ref-type="bibr" rid="B79-ijms-21-04391">79</xref>,<xref ref-type="bibr" rid="B80-ijms-21-04391">80</xref>,<xref ref-type="bibr" rid="B81-ijms-21-04391">81</xref>,<xref ref-type="bibr" rid="B82-ijms-21-04391">82</xref>]. A study in 16 individuals with FXTAS found that sensory axonal neuropathy was the most predominant characteristic of neuropathy in FXTAS with reduction of the sensory nerve action potential amplitude demonstrated in nerve conduction studies [<xref ref-type="bibr" rid="B76-ijms-21-04391">76</xref>]. All extremities could be involved and both non-length-dependent and length-dependent sensory neuropathy were described [<xref ref-type="bibr" rid="B76-ijms-21-04391">76</xref>]. In addition, motor neuropathy has also been observed [<xref ref-type="bibr" rid="B76-ijms-21-04391">76</xref>,<xref ref-type="bibr" rid="B79-ijms-21-04391">79</xref>,<xref ref-type="bibr" rid="B83-ijms-21-04391">83</xref>]. In male carriers, the severity of neuropathic signs and degree of changes in nerve conduction studies correlated with the number of CGG repeats, mRNA level, and having ataxia [<xref ref-type="bibr" rid="B81-ijms-21-04391">81</xref>,<xref ref-type="bibr" rid="B83-ijms-21-04391">83</xref>]. Intranuclear inclusions in the dorsal root ganglia might underlie neurodegeneration which causes the neuropathy [<xref ref-type="bibr" rid="B48-ijms-21-04391">48</xref>,<xref ref-type="bibr" rid="B84-ijms-21-04391">84</xref>].</p>
</sec>
<sec id="sec3dot4-ijms-21-04391">
<title>3.4. Parkinsonism</title>
<p>Parkinsonism has been found in approximately 29–60% of carriers with FXTAS and it is usually mild [<xref ref-type="bibr" rid="B18-ijms-21-04391">18</xref>,<xref ref-type="bibr" rid="B56-ijms-21-04391">56</xref>,<xref ref-type="bibr" rid="B76-ijms-21-04391">76</xref>,<xref ref-type="bibr" rid="B77-ijms-21-04391">77</xref>]. A variety of parkinsonian features have been observed in FXTAS. Mild bradykinesia, rigidity of the upper extremities while performing mirror movements, masked facies, and rest tremor have been reported. Bradykinesia is correlated with the level of <italic>FMR1</italic> mRNA, ataxia, and the stage of FXTAS [<xref ref-type="bibr" rid="B18-ijms-21-04391">18</xref>,<xref ref-type="bibr" rid="B56-ijms-21-04391">56</xref>,<xref ref-type="bibr" rid="B77-ijms-21-04391">77</xref>]. The presence of bradykinesia with cerebellar gait ataxia and mixed tremor should alert physicians to recognize FXTAS in the differential diagnosis of Parkinson’s disease [<xref ref-type="bibr" rid="B77-ijms-21-04391">77</xref>].</p>
</sec>
<sec id="sec3dot5-ijms-21-04391">
<title>3.5. Eye Gaze Abnormalities</title>
<p>Eye gaze abnormalities have been described in patients with FXTAS, especially impaired optokinetic nystagmus in the vertical direction, slowing of vertical saccades, saccadic pursuits, and square wave jerks [<xref ref-type="bibr" rid="B82-ijms-21-04391">82</xref>,<xref ref-type="bibr" rid="B85-ijms-21-04391">85</xref>]. These findings are referred to as the progressive supranuclear palsy (PSP)-like phenotype of FXTAS. Brainstem atrophy particularly in the midbrain region has been found in both FXTAS and PSP, although it is unclear whether they are co-occurrences or whether FXTAS promotes PSP changes in the phenotype [<xref ref-type="bibr" rid="B82-ijms-21-04391">82</xref>]. Further pathological studies will clarify the primary mechanism.</p>
</sec>
<sec id="sec3dot6-ijms-21-04391">
<title>3.6. Cognitive Impairment</title>
<p>Approximately half of males with FXTAS have cognitive impairment while females are less affected [<xref ref-type="bibr" rid="B56-ijms-21-04391">56</xref>,<xref ref-type="bibr" rid="B60-ijms-21-04391">60</xref>,<xref ref-type="bibr" rid="B86-ijms-21-04391">86</xref>,<xref ref-type="bibr" rid="B87-ijms-21-04391">87</xref>]. Executive dysfunction is the core cognitive deficit in FXTAS. Behavioral self-regulation, verbal fluency, working memory, remote recall, declarative verbal learning memory, visuospatial function, temporal sequencing, information processing speed, and general intelligence, specifically nonverbal intellectual quotient, are often found to be impaired in individuals with FXTAS [<xref ref-type="bibr" rid="B88-ijms-21-04391">88</xref>,<xref ref-type="bibr" rid="B89-ijms-21-04391">89</xref>,<xref ref-type="bibr" rid="B90-ijms-21-04391">90</xref>]. The impairment is correlated with CGG repeat number [<xref ref-type="bibr" rid="B65-ijms-21-04391">65</xref>,<xref ref-type="bibr" rid="B88-ijms-21-04391">88</xref>,<xref ref-type="bibr" rid="B89-ijms-21-04391">89</xref>] and it worsens over time. Milder cognitive impairment can sometimes affect non-FXTAS carriers who are also aging [<xref ref-type="bibr" rid="B90-ijms-21-04391">90</xref>]. Cognitive decline sometimes precedes motor problems, and carriers with mid-range CGG repeats have the highest relative risk compared to carriers with lower or higher CGG repeats [<xref ref-type="bibr" rid="B86-ijms-21-04391">86</xref>,<xref ref-type="bibr" rid="B91-ijms-21-04391">91</xref>].</p>
<p>Unlike dementia in Alzheimer’s disease which usually affects memory and language performance; executive dysfunction and verbal dysfluency which reflect cortical-subcortical dementia are distinct in FXTAS [<xref ref-type="bibr" rid="B87-ijms-21-04391">87</xref>]. In addition, FXTAS has a higher penetrance in males and should be suspected in patients presenting with dementia and atypical parkinsonian syndrome [<xref ref-type="bibr" rid="B87-ijms-21-04391">87</xref>]. Moreover, compared to mothers of children with ASD who were considered to have similar parental experiences to the PM mothers of children with FXS, the latter group had higher scores in verbal dysfluency and impaired self-monitoring [<xref ref-type="bibr" rid="B92-ijms-21-04391">92</xref>]. Furthermore, in a study by Nayar and colleagues, they examined language processing skills in 46 females with the PM and 56 controls and they found a pattern of inefficient language processing among the females with the PM [<xref ref-type="bibr" rid="B93-ijms-21-04391">93</xref>]. In individuals with FXTAS, it is necessary to address cognitive impairment and implement early intervention since impaired information processing speed, response inhibition, and working memory could interfere with their mobility [<xref ref-type="bibr" rid="B94-ijms-21-04391">94</xref>].</p>
</sec>
<sec id="sec3dot7-ijms-21-04391">
<title>3.7. Other Coexisting Conditions</title>
<p>Autonomic dysfunction is common in males with FXTAS. Impotence (56–80%), hypertension (50–67%), and orthostatic hypotension (16%) usually present before the onset of motor symptoms. Bowel (30%) and bladder dysfunction (24–55%) occur at later stages of FXTAS [<xref ref-type="bibr" rid="B18-ijms-21-04391">18</xref>,<xref ref-type="bibr" rid="B50-ijms-21-04391">50</xref>,<xref ref-type="bibr" rid="B56-ijms-21-04391">56</xref>]. In both sexes, individuals with FXTAS have higher odds of having hypertension compared with age-matched noncarriers and the risk of having hypertension is related to <italic>FMR1</italic> mRNA levels [<xref ref-type="bibr" rid="B47-ijms-21-04391">47</xref>,<xref ref-type="bibr" rid="B50-ijms-21-04391">50</xref>,<xref ref-type="bibr" rid="B51-ijms-21-04391">51</xref>]. Cardiac arrhythmia is not uncommon and several reports have consistently described individuals with FXTAS who presented with arrhythmias that required a cardiac pacemaker [<xref ref-type="bibr" rid="B43-ijms-21-04391">43</xref>,<xref ref-type="bibr" rid="B67-ijms-21-04391">67</xref>,<xref ref-type="bibr" rid="B75-ijms-21-04391">75</xref>]. Recently sudden coronary artery dissection (SCAD) has been reported in three older females with the premutation [<xref ref-type="bibr" rid="B95-ijms-21-04391">95</xref>]. Rare symptoms of autonomic dysregulation have been reported in individuals with FXTAS including postprandial hypotension [<xref ref-type="bibr" rid="B96-ijms-21-04391">96</xref>] and postprandial syncope [<xref ref-type="bibr" rid="B97-ijms-21-04391">97</xref>].</p>
<p>Sleep problems, especially obstructive sleep apnea (OSA), are diagnosed in about one-third of the carriers with FXTAS [<xref ref-type="bibr" rid="B52-ijms-21-04391">52</xref>,<xref ref-type="bibr" rid="B56-ijms-21-04391">56</xref>]. One-third of the PM carriers also have restless legs syndrome [<xref ref-type="bibr" rid="B53-ijms-21-04391">53</xref>].</p>
<p>Neuropsychiatric problems are quite common in carriers and usually present early in life. Anxiety and depression are found in half of the PM carriers and the prevalence is higher in FXTAS [<xref ref-type="bibr" rid="B61-ijms-21-04391">61</xref>,<xref ref-type="bibr" rid="B62-ijms-21-04391">62</xref>]. Executive dysfunction, imbalance of GABA and glutamate functions, chronic medical conditions, and caring for children with FXS might be potential risk factors for these neuropsychiatric problems [<xref ref-type="bibr" rid="B9-ijms-21-04391">9</xref>]. However once FXTAS begins, often depression, apathy, irritability, and social avoidance are common and usually worsen with cognitive decline [<xref ref-type="bibr" rid="B98-ijms-21-04391">98</xref>].</p>
<p>Some clinical characteristics are more prevalent in females with the premutation compared to males. Half of the females with the premutation have a history of migraine headaches in contrast with only one-fourth of male carriers [<xref ref-type="bibr" rid="B54-ijms-21-04391">54</xref>]. Thyroid dysfunction, specifically hypothyroidism, is found in 50% of females with FXTAS [<xref ref-type="bibr" rid="B64-ijms-21-04391">64</xref>]. More than 25% of females with FXTAS are reported to have fibromyalgia [<xref ref-type="bibr" rid="B51-ijms-21-04391">51</xref>,<xref ref-type="bibr" rid="B63-ijms-21-04391">63</xref>,<xref ref-type="bibr" rid="B64-ijms-21-04391">64</xref>]. These symptoms are usually problematic even in mid-adulthood and they commonly require medical treatment.</p>
</sec>
</sec>
<sec id="sec4-ijms-21-04391">
<title>4. Neuroradiological Findings</title>
<p>Radiological findings, which are discussed here, were inferred from studies in males with FXTAS. Bilateral hyperintensities of the middle cerebellar peduncles (MCP sign) on T2-weighted MR or FLAIR images is the hallmark of FXTAS [<xref ref-type="bibr" rid="B18-ijms-21-04391">18</xref>]. The sign can even be seen in some carriers without remarkable neurological symptoms [<xref ref-type="bibr" rid="B99-ijms-21-04391">99</xref>,<xref ref-type="bibr" rid="B100-ijms-21-04391">100</xref>,<xref ref-type="bibr" rid="B101-ijms-21-04391">101</xref>,<xref ref-type="bibr" rid="B102-ijms-21-04391">102</xref>]. Hyperintensities are also commonly observed in the periventricular white matter, the splenium of the corpus callosum, and the brainstem [<xref ref-type="bibr" rid="B76-ijms-21-04391">76</xref>,<xref ref-type="bibr" rid="B103-ijms-21-04391">103</xref>], although these signs are not specific to FXTAS. The MCP sign is found in 58–82% of males and 13% of females with FXTAS [<xref ref-type="bibr" rid="B103-ijms-21-04391">103</xref>,<xref ref-type="bibr" rid="B104-ijms-21-04391">104</xref>] while the splenium hyperintensity is observed in approximately 60% of the patients, equivalently in both sexes [<xref ref-type="bibr" rid="B103-ijms-21-04391">103</xref>].</p>
<p>Brain atrophy and general brain volume loss have been described in several studies. Atrophy can be found in the entire cerebrum and cerebellum, particularly in the dorsomedial frontal-parietal regions, insula, medial temporal regions, thalamus, and striatum [<xref ref-type="bibr" rid="B18-ijms-21-04391">18</xref>,<xref ref-type="bibr" rid="B105-ijms-21-04391">105</xref>,<xref ref-type="bibr" rid="B106-ijms-21-04391">106</xref>,<xref ref-type="bibr" rid="B107-ijms-21-04391">107</xref>]. Ventricular enlargement is also present in the later stages of FXTAS as well as thinning of the corpus callosum [<xref ref-type="bibr" rid="B105-ijms-21-04391">105</xref>,<xref ref-type="bibr" rid="B108-ijms-21-04391">108</xref>,<xref ref-type="bibr" rid="B109-ijms-21-04391">109</xref>]. In females with FXTAS, the magnitude of cerebellar volume loss and the severity of white matter disease is less than in males [<xref ref-type="bibr" rid="B104-ijms-21-04391">104</xref>].</p>
<p>The number of CGG repeats associates with the degree of structural brain changes. Increasing CGG repeat numbers correlate with a greater degree of cerebral and cerebellar atrophy in male carriers [<xref ref-type="bibr" rid="B104-ijms-21-04391">104</xref>], volume loss in the supplementary motor area and the dorsomedial prefrontal cortex [<xref ref-type="bibr" rid="B106-ijms-21-04391">106</xref>], ventricular enlargement, and whole-brain white matter hyperintensity and volume [<xref ref-type="bibr" rid="B108-ijms-21-04391">108</xref>,<xref ref-type="bibr" rid="B109-ijms-21-04391">109</xref>,<xref ref-type="bibr" rid="B110-ijms-21-04391">110</xref>]. In addition, diffusion tensor imaging (DTI) studies revealed abnormalities of the white matter fiber tracts of the middle and superior cerebellar peduncles, and these findings are correlated with CGG repeat number and <italic>FMR1</italic> mRNA level [<xref ref-type="bibr" rid="B111-ijms-21-04391">111</xref>,<xref ref-type="bibr" rid="B112-ijms-21-04391">112</xref>].</p>
<p>These radiological abnormalities which are in various brain regions correlate to clinical manifestations of FXTAS [<xref ref-type="bibr" rid="B113-ijms-21-04391">113</xref>]. For instance, motor control and dexterity relate to the abnormal findings in the corpus callosum and superior cerebellar peduncle [<xref ref-type="bibr" rid="B114-ijms-21-04391">114</xref>]. Cerebellar atrophy might result in postural instability [<xref ref-type="bibr" rid="B115-ijms-21-04391">115</xref>]. Widespread white matter hyperintensities and grey matter loss as well as decreased prefrontal cortex activity are correlated with compromised cognitive and executive functions [<xref ref-type="bibr" rid="B106-ijms-21-04391">106</xref>,<xref ref-type="bibr" rid="B108-ijms-21-04391">108</xref>,<xref ref-type="bibr" rid="B116-ijms-21-04391">116</xref>,<xref ref-type="bibr" rid="B117-ijms-21-04391">117</xref>]. Reduced hippocampal volume and left amygdala grey matter loss is associated with increasing of psychiatric symptoms [<xref ref-type="bibr" rid="B106-ijms-21-04391">106</xref>,<xref ref-type="bibr" rid="B115-ijms-21-04391">115</xref>,<xref ref-type="bibr" rid="B118-ijms-21-04391">118</xref>].</p>
</sec>
<sec id="sec5-ijms-21-04391">
<title>5. Pathophysiology</title>
<sec id="sec5dot1-ijms-21-04391">
<title>5.1. Molecular Mechanisms</title>
<p>The neurotoxic effect of increased levels of <italic>FMR1</italic> mRNA has been proposed as the main alteration leading to the development of FXTAS [<xref ref-type="bibr" rid="B12-ijms-21-04391">12</xref>]; increased levels of mRNA also cause Ca<sup>+2</sup> dysregulation followed by mitochondrial dysfunction [<xref ref-type="bibr" rid="B119-ijms-21-04391">119</xref>,<xref ref-type="bibr" rid="B120-ijms-21-04391">120</xref>]. Three different molecular mechanisms have been studied with the aim of understanding the molecular abnormalities resulting in the neuropathology of FXTAS: (1) the production of toxic FMRpolyG by repeat associated non-AUG (RAN) translation, (2) RNAs and protein sequestration into intranuclear inclusions and (3) DNA damage caused by R-loop formation.</p>
<p>The first proposed mechanism is RAN translation [<xref ref-type="bibr" rid="B121-ijms-21-04391">121</xref>]. RAN translation is common in triplet expansion disorders. This error in translation leads to anomalous peptide synthesis [<xref ref-type="bibr" rid="B121-ijms-21-04391">121</xref>,<xref ref-type="bibr" rid="B122-ijms-21-04391">122</xref>,<xref ref-type="bibr" rid="B123-ijms-21-04391">123</xref>,<xref ref-type="bibr" rid="B124-ijms-21-04391">124</xref>,<xref ref-type="bibr" rid="B125-ijms-21-04391">125</xref>]. Particularly in FXTAS, the noncoding region of <italic>FMR1</italic> premutation mRNA is translated into multiple RAN translation peptides, as seen in <xref ref-type="fig" rid="ijms-21-04391-f002">Figure 2</xref>, including the FMRpolyG peptide [<xref ref-type="bibr" rid="B121-ijms-21-04391">121</xref>,<xref ref-type="bibr" rid="B126-ijms-21-04391">126</xref>]. This peptide has been found to be toxic by disrupting the architecture of the nuclear lamina due to its interaction with the transmembrane protein lamina-associated polypeptide 2 beta (LAP2β) in differentiated neurons derived from FXTAS induced pluripotent stem (iPS) cells. The length of FMRpolyG correlates with the number of CGG repeats; it is detected in CGG expansions ranging from 60 to 200 repeats and it is also present in the intranuclear inclusions pathognomonic of FXTAS in the <italic>FMR1</italic> premutation transgenic animal models [<xref ref-type="bibr" rid="B126-ijms-21-04391">126</xref>].</p>
<p>The second mechanism is the sequestration of RNA and other proteins by the <italic>FMR1</italic> premutation mRNA forming intranuclear inclusions, disrupting essential cellular processes. Protein sequestration renders the cell functionally deficient from proteins that play an important role in multiple cellular mechanisms such as splicing (heterogeneous nuclear ribonucleoproteins A2/B1 protein (hnRNP A2/B1)), mRNA transportation in the cytoplasm (hnRNP A2/B1, Pur-alpha), microRNA processing (DiGeorge Syndrome Critical Region 8 (DGCR8) protein and Drosha complex), and formation of heterochromatin (heterochromatin protein 1 (HP1)) [<xref ref-type="bibr" rid="B127-ijms-21-04391">127</xref>,<xref ref-type="bibr" rid="B128-ijms-21-04391">128</xref>]. <xref ref-type="fig" rid="ijms-21-04391-f003">Figure 3</xref> shows the proteins involved in <italic>FMR1</italic> RNA-induced sequestration. Ubiquitin positive inclusions are the hallmark of FXTAS [<xref ref-type="bibr" rid="B75-ijms-21-04391">75</xref>,<xref ref-type="bibr" rid="B129-ijms-21-04391">129</xref>,<xref ref-type="bibr" rid="B130-ijms-21-04391">130</xref>]; they contain <italic>FMR1</italic> mRNA but lack FMRP [<xref ref-type="bibr" rid="B131-ijms-21-04391">131</xref>,<xref ref-type="bibr" rid="B132-ijms-21-04391">132</xref>]. Inclusions are an aggregate of protein, composed of a heterogeneous assortment of many peptides. The DNA damage response proteins found in the inclusions form in response to oxidative stress leading to neurodegeneration [<xref ref-type="bibr" rid="B132-ijms-21-04391">132</xref>]. The mechanisms by which protein sequestration leads to toxicity and disease are currently being studied.</p>
<p>The third proposed molecular mechanism involves the formation of RNA/DNA hybrids or R-loops during transcription. R-loops form during the CGG triplet expansion at the <italic>FMR1</italic> locus causing vulnerability to DNA damage [<xref ref-type="bibr" rid="B133-ijms-21-04391">133</xref>]. These R-loops are more frequently formed in the nontemplate strand containing guanine-rich sequences [<xref ref-type="bibr" rid="B134-ijms-21-04391">134</xref>,<xref ref-type="bibr" rid="B135-ijms-21-04391">135</xref>]. These folded structures remain unpaired and lead to genome instability [<xref ref-type="bibr" rid="B136-ijms-21-04391">136</xref>]. The sites become fragile and are prone to DNA damage including deletions and translocations. DNA damage should be corrected by the DNA damage response (DDR) molecular signaling pathway [<xref ref-type="bibr" rid="B137-ijms-21-04391">137</xref>]. However, this response appears to be impaired in FXTAS [<xref ref-type="bibr" rid="B138-ijms-21-04391">138</xref>].</p>
<p>The molecular mechanisms presented here do not exclude one another; on the contrary, there may exist a synergistic effect from different dysfunctional processes at the molecular level leading to FXTAS. The mitochondrial abnormalities present in FXTAS may worsen over time and lead to loss of energy and strength in the patients and perhaps neuronal cell death and white matter disease over time [<xref ref-type="bibr" rid="B119-ijms-21-04391">119</xref>,<xref ref-type="bibr" rid="B139-ijms-21-04391">139</xref>,<xref ref-type="bibr" rid="B140-ijms-21-04391">140</xref>,<xref ref-type="bibr" rid="B141-ijms-21-04391">141</xref>]. Many additional mechanisms causing neuropathology and toxicity may remain unrecognized.</p>
</sec>
<sec id="sec5dot2-ijms-21-04391">
<title>5.2. Pathology</title>
<p>One of the neuropathological hallmarks of FXTAS is the presence of eosinophilic intranuclear inclusions in the CNS and peripheral nervous system [<xref ref-type="bibr" rid="B22-ijms-21-04391">22</xref>,<xref ref-type="bibr" rid="B84-ijms-21-04391">84</xref>]. The presence of inclusions in neurons and astrocytes constitutes a major criterion for the diagnosis of FXTAS [<xref ref-type="bibr" rid="B22-ijms-21-04391">22</xref>,<xref ref-type="bibr" rid="B142-ijms-21-04391">142</xref>]. These intranuclear inclusions were first identified in neurons and astrocytes in the brain in 2002 by Greco and colleagues [<xref ref-type="bibr" rid="B129-ijms-21-04391">129</xref>]. Inclusions occur broadly throughout the CNS with regional variability in the proportion of cells bearing the inclusions [<xref ref-type="bibr" rid="B143-ijms-21-04391">143</xref>]. Neurons and astrocytes positive for the presence of inclusions are mostly prevalent in the hippocampus (up to 40% of cells), followed by the frontal and the temporal cortex [<xref ref-type="bibr" rid="B67-ijms-21-04391">67</xref>,<xref ref-type="bibr" rid="B75-ijms-21-04391">75</xref>,<xref ref-type="bibr" rid="B129-ijms-21-04391">129</xref>]. These inclusions have also been identified in the basal ganglia [<xref ref-type="bibr" rid="B97-ijms-21-04391">97</xref>]. Further studies identified these inclusions in the peripheral nervous system, mainly in the autonomic system [<xref ref-type="bibr" rid="B48-ijms-21-04391">48</xref>], and other non-CNS locations such as neuroendocrine tissue, heart, and kidney [<xref ref-type="bibr" rid="B84-ijms-21-04391">84</xref>,<xref ref-type="bibr" rid="B97-ijms-21-04391">97</xref>,<xref ref-type="bibr" rid="B144-ijms-21-04391">144</xref>].</p>
<p>Various studies have been conducted in order to elucidate the features of the inclusions. These eosinophilic inclusions have shown to stain positive for ubiquitin, lamin A/C and various heat-shock proteins, and their biochemical composition is very heterogeneous with no single predominant protein species [<xref ref-type="bibr" rid="B131-ijms-21-04391">131</xref>]. Mass spectrometric and immunohistochemical analysis in postmortem FXTAS brain tissue have identified more than 20 inclusion-associated proteins including RNA-binding protein, hnRNP A2, intermediate filament proteins, and other neurofilament proteins [<xref ref-type="bibr" rid="B75-ijms-21-04391">75</xref>,<xref ref-type="bibr" rid="B129-ijms-21-04391">129</xref>,<xref ref-type="bibr" rid="B131-ijms-21-04391">131</xref>]. <italic>FMR1</italic> mRNA was also identified but as a minor component [<xref ref-type="bibr" rid="B145-ijms-21-04391">145</xref>]. More recently, Ma and colleagues conducted a study of the composition of the intranuclear inclusions of FXTAS using fluorescence-activated cell sorting (FACS) and liquid chromatography/tandem mass spectrometry-based proteomics. They identified more than 200 proteins which are normally involved in RNA binding, protein turnover, and DNA damage repair [<xref ref-type="bibr" rid="B132-ijms-21-04391">132</xref>]. It is noteworthy that the presence of intranuclear inclusions has also been identified in a carrier with no clinical symptoms associated with FXTAS, although this carrier was bedridden with severe ataxia and perhaps other symptoms associated with FXTAS by the time she died, so it is uncertain if the presence of inclusions always means FXTAS, but this is likely the case [<xref ref-type="bibr" rid="B67-ijms-21-04391">67</xref>].</p>
<p>Iron metabolic pathway dysregulation has been identified as a mechanism underlying the neuropathology of FXTAS and therefore as a potential targeted treatment. Postmortem FXTAS brains present with iron accumulation in brain capillaries and parenchyma, as well as in the choroid plexus [<xref ref-type="bibr" rid="B146-ijms-21-04391">146</xref>,<xref ref-type="bibr" rid="B147-ijms-21-04391">147</xref>,<xref ref-type="bibr" rid="B148-ijms-21-04391">148</xref>]. Severe iron accumulation is a common finding in the striatum and less commonly in the cerebrum [<xref ref-type="bibr" rid="B146-ijms-21-04391">146</xref>]. There is a decreased amount of transferrin and ceruloplasmin, which are iron-binding proteins, in neurons and astrocytes, whereas there are increased levels of these proteins in the microglial cells, which indicates an attempt to respond to excessive iron accumulation [<xref ref-type="bibr" rid="B146-ijms-21-04391">146</xref>]. Studies have demonstrated substantial iron bound to hemosiderin accumulated in the putamen [<xref ref-type="bibr" rid="B146-ijms-21-04391">146</xref>,<xref ref-type="bibr" rid="B147-ijms-21-04391">147</xref>,<xref ref-type="bibr" rid="B149-ijms-21-04391">149</xref>], which on neuroimaging can be detected as symmetric hypointensities in the putamen and caudate in T2-weighted MRI [<xref ref-type="bibr" rid="B85-ijms-21-04391">85</xref>,<xref ref-type="bibr" rid="B114-ijms-21-04391">114</xref>].</p>
<p>Since FXTAS is associated with high levels of oxidative stress in the brain and an inflammatory state, and considering that microglia-mediated neuroinflammation plays a major role in the pathogenesis of neurodegenerative diseases, it was proposed that microglial activation could contribute to FXTAS pathology [<xref ref-type="bibr" rid="B150-ijms-21-04391">150</xref>]. In a study of 13 FXTAS brain specimens, Martínez-Cerdeño and colleagues found that almost half of FXTAS brains presented with dystrophic senescent microglial cells, suggesting that these could be used in association with the presence of intranuclear inclusions and iron deposits as a marker in the postmortem diagnosis of FXTAS [<xref ref-type="bibr" rid="B150-ijms-21-04391">150</xref>]. They also found that the presence of senescent microglia was correlated with the CGG repeat number and with iron accumulation. This suggests that microglial cells are involved in the neuroinflammatory state of FXTAS and that they can serve as a pathological criterion for the diagnosis.</p>
<p>FXTAS can coexist with other neurodegenerative diseases. Salcedo-Arellano and colleagues conducted a study to describe the frequency of Parkinson’s disease and concomitant FXTAS [<xref ref-type="bibr" rid="B151-ijms-21-04391">151</xref>]. They reviewed medical records and performed a pathology analysis on 40 deceased patients with a diagnosis of FXTAS. They found that 5% of the brains of 40 patients met pathologic criteria for both Parkinson’s disease, based on the presence of Lewy bodies in the substantia nigra and nigral neuronal loss, as well as FXTAS. In the case of Alzheimer’s disease, some patients with FXTAS and dementia symptomology presented with concurrent findings of Alzheimer’s neuropathology such as amyloid plaques and neurofibrillary tangles [<xref ref-type="bibr" rid="B67-ijms-21-04391">67</xref>]. Various case reports of patients with FXTAS and coexisting Alzheimer’s disease or Parkinson’s disease suggest a synergistic effect on the progression of FXTAS and the concomitant neurodegenerative disease [<xref ref-type="bibr" rid="B67-ijms-21-04391">67</xref>,<xref ref-type="bibr" rid="B152-ijms-21-04391">152</xref>,<xref ref-type="bibr" rid="B153-ijms-21-04391">153</xref>].</p>
<p>Finally, macroscopic pathological findings of brains from patients with FXTAS reveal severe white matter disease, cortical atrophy and mild to severe ventriculomegaly and spongiosis of cerebellar white matter [<xref ref-type="bibr" rid="B67-ijms-21-04391">67</xref>,<xref ref-type="bibr" rid="B75-ijms-21-04391">75</xref>,<xref ref-type="bibr" rid="B129-ijms-21-04391">129</xref>]. Grey matter atrophy is most consistently found in the frontal cortex, cerebellum, and the pons [<xref ref-type="bibr" rid="B75-ijms-21-04391">75</xref>,<xref ref-type="bibr" rid="B129-ijms-21-04391">129</xref>].</p>
</sec>
</sec>
<sec id="sec6-ijms-21-04391">
<title>6. Diagnosis</title>
<sec id="sec6dot1-ijms-21-04391">
<title>6.1. Diagnostic Criteria for FXTAS</title>
<p>As described earlier, FXTAS is characterized by multiple clinical signs, although there is heterogeneity in the severity depending on the sex of the patient, CGG repeat size, and length of disease. For the diagnosis of FXTAS a molecular diagnosis of an <italic>FMR1</italic> gene mutation, including the gray zone, is needed. It is important to know the CGG repeat size since it correlates negatively with the age of onset of symptoms [<xref ref-type="bibr" rid="B41-ijms-21-04391">41</xref>] and it correlates positively with the severity of motor signs and brain atrophy [<xref ref-type="bibr" rid="B40-ijms-21-04391">40</xref>,<xref ref-type="bibr" rid="B154-ijms-21-04391">154</xref>]. The diagnostic criteria for FXTAS were established for the first time in 2003 [<xref ref-type="bibr" rid="B18-ijms-21-04391">18</xref>] and later revised in 2014 to expand the radiological and clinical criteria [<xref ref-type="bibr" rid="B155-ijms-21-04391">155</xref>]. Due to reports of FXTAS in patients with the gray zone and FM with a lack of methylation or mosaic alleles, the molecular criteria is now considered to be any <italic>FMR1</italic> alteration [<xref ref-type="bibr" rid="B13-ijms-21-04391">13</xref>,<xref ref-type="bibr" rid="B14-ijms-21-04391">14</xref>]. See <xref ref-type="table" rid="ijms-21-04391-t001">Table 1</xref> for FXTAS diagnostic criteria and diagnostic categories. When FXTAS is suspected, the clinician needs to perform molecular, clinical, and neuroradiological evaluations. The <italic>FMR1</italic> gene testing characterizes the <italic>FMR1</italic> mutation, including the gray zone (45 to 54 CGG repeats), which is the only required criteria. A brain MRI allows the evaluation of white matter lesions and brain atrophy; with the presence of white matter lesions in the MCP or brainstem constituting a major radiological sign. These radiological criteria are evaluated on axial flair T2-weighted magnetic resonance images. <xref ref-type="fig" rid="ijms-21-04391-f004">Figure 4</xref> shows the neuroradiological findings that are part of the diagnostic criteria for FXTAS. A thorough clinical evaluation to assess for intention tremor, cerebellar ataxia, parkinsonism, neuropathy, memory impairment, and executive function deficits is essential for the diagnosis.</p>
<p>When should a physician consider genetic testing for <italic>FMR1</italic> and a FXTAS diagnosis? There are guidelines indicating when and whom to test for <italic>FMR1</italic> gene mutations [<xref ref-type="bibr" rid="B156-ijms-21-04391">156</xref>]. Expansions in <italic>FMR1</italic> are diagnosed in relatives as part of cascade testing when a child is diagnosed with FXS or when a woman in the context of fertility testing is diagnosed with the PM and FXPOI [<xref ref-type="bibr" rid="B12-ijms-21-04391">12</xref>]. When a clinician encounters a patient with any of the various clinical signs consistent with FXTAS, they should perform a thorough family history and ask further about <italic>FMR1</italic>-related conditions. Questions should include features of FXS such as developmental delay, intellectual disability, and autism spectrum disorders. Questions related to PM carrier status include the age of menopause and features of menopause before the age of 40 for FXPOI, psychiatric symptoms such as anxiety, and movement disorders. A clinician evaluating a patient with a new onset of ataxia or intention tremor and a history of a grandchild with autism or developmental delay of unknown etiology should consider FXTAS among the differential diagnosis.</p>
</sec>
<sec id="sec6dot2-ijms-21-04391">
<title>6.2. Differential Diagnosis</title>
<p>When evaluating for FXTAS, the clinician must consider and rule out other causes of dementia, especially reversible causes. The differential diagnosis of FXTAS is broad and some neurodegenerative diseases may coexist. Among the differential diagnosis of FXTAS are movement disorders and dementias such as late-onset cerebellar ataxia, spinocerebellar ataxia, multiple system atrophy, Alzheimer’s disease, frontotemporal dementia, and Parkinson’s disease. Robertson and colleagues reviewed the cognitive and motor impairments in FXTAS and compared it with other movement disorders that patients with FXTAS are sometimes misdiagnosed with [<xref ref-type="bibr" rid="B157-ijms-21-04391">157</xref>]. Since there may be symptomatology overlap, it is important to know the most common presentations and the distinct profiles in cognitive and motor domains to guide the diagnostic process.</p>
</sec>
</sec>
<sec id="sec7-ijms-21-04391">
<title>7. Management and Ongoing Research</title>
<p>FXTAS is a neurodegenerative disorder caused by RNA toxicity and mitochondrial dysfunction related to <italic>FMR1</italic> gene mutations. Principles of management include maintaining a healthy lifestyle and treatment of coexisting conditions to prevent rapid progression of FXTAS. Hypertension, OSA, hypothyroidism, neuropsychiatric disorders, and vitamin deficiencies can potentiate cognitive decline. These conditions need to be evaluated and treated in all PM carriers [<xref ref-type="bibr" rid="B158-ijms-21-04391">158</xref>]. To date, there are not any targeted treatments that will reverse FXTAS, but some medications may help symptoms of FXTAS such as a selective serotonin reuptake inhibitor (SSRI) for depression or anxiety, a beta blocker, primidone or levetiracetam for tremor, and gabapentin, pregabalin or duloxetine for neuropathic pain [<xref ref-type="bibr" rid="B12-ijms-21-04391">12</xref>]. Many studies have investigated benefits of medications that have been used for other neurodegenerative disorders. We will mention the drugs that have been studied in clinical trials in patients with FXTAS and have published results to date.</p>
<p>Memantine is a medicament that blocks the <italic>N</italic>-methyl-d-aspartate (NMDA) receptor which is a subtype of glutamate receptor [<xref ref-type="bibr" rid="B159-ijms-21-04391">159</xref>]. It has been approved for the treatment of Alzheimer’s disease. A randomized controlled trial was conducted in 94 individuals with FXTAS in which memantine titrated to 10 mg was prescribed to 43 participants. After one year follow-up, the memantine group had a comparable degree of tremor, executive function score, and verbal fluency score compared to the control group [<xref ref-type="bibr" rid="B160-ijms-21-04391">160</xref>]. An inadequate sample size and few participants with later stages of FXTAS might have compromised the power of the study. However, subsequent studies in the same participants found benefits of memantine on verbal memory, attention, and working memory which were evaluated by using event-related potential (ERP) [<xref ref-type="bibr" rid="B161-ijms-21-04391">161</xref>,<xref ref-type="bibr" rid="B162-ijms-21-04391">162</xref>]. Therefore, memantine appears to be helpful for auditory processing involved in attention and aspects of cognition including memory, and it can be tried in patients with FXTAS.</p>
<p>Allopregnanolone is a neurosteroid that is synthesized from progesterone. It is a potent positive allosteric modulator and acts on GABA<sub>A</sub> receptor. Therefore, allopregnanolone might promote neurogenesis and has neuroprotective effects. An open-label trial of weekly titrated 2 to 6 mg of intravenous allopregnanolone for 12 weeks was studied in six males aged 57–74 years diagnosed with the PM and FXTAS stages 3–5 [<xref ref-type="bibr" rid="B163-ijms-21-04391">163</xref>,<xref ref-type="bibr" rid="B164-ijms-21-04391">164</xref>]. Improvement of scores in executive function, memory, and learning was noted [<xref ref-type="bibr" rid="B163-ijms-21-04391">163</xref>,<xref ref-type="bibr" rid="B164-ijms-21-04391">164</xref>], especially in the participants with preserved hippocampus and corpus callosum sizes on MRI [<xref ref-type="bibr" rid="B164-ijms-21-04391">164</xref>]. Semantic processing and verbal learning memory, which was measured by ERP N400 word repetition effect while performing a semantic memory processing task, was also improved [<xref ref-type="bibr" rid="B164-ijms-21-04391">164</xref>]. One patient had a dramatic improvement in neuropathy symptoms. Decreased anxiety symptoms were also observed in the participants with small hippocampus and amygdala [<xref ref-type="bibr" rid="B164-ijms-21-04391">164</xref>]. Allopregnanolone treatment significantly improved GABA metabolism and metabolites of mitochondrial function and reduced oxidative stress. It also increased N-acetylornithine which might improve motor control [<xref ref-type="bibr" rid="B163-ijms-21-04391">163</xref>].</p>
<p>Citicoline, cytidine-5-diphosphocholine, is essential for cell membrane stabilization and inhibition of free radicals. It has been used for the treatment of head trauma, ischemic cerebrovascular disease, and neurodegenerative disease [<xref ref-type="bibr" rid="B165-ijms-21-04391">165</xref>]. Recently, an open-label phase II pilot study of citicoline was conducted in ten participants aged 70 ± 7.3 years old with CGG 91.5 ± 15.6 repeats and FXTAS stage 1–3 [<xref ref-type="bibr" rid="B166-ijms-21-04391">166</xref>]. Citicoline in a dose of 1000 mg was prescribed once daily for 12 months. Stable motor functions were observed after 1-year citicoline, evidenced by no significant change in FXTAS rating scale (FXTAS-RS), which is a tool designed to measure the severity of motor symptoms in FXTAS. However, citicoline had promising results in other secondary outcomes: it showed improvement of anxiety and response inhibition without causing serious adverse events. Control clinical trials are needed to confirm the findings.</p>
<p>Although to date, only three clinical trials evaluating potential therapeutic targeted treatments have been completed, other compounds such as curcumin and piperine have shown promising preclinical results [<xref ref-type="bibr" rid="B167-ijms-21-04391">167</xref>,<xref ref-type="bibr" rid="B168-ijms-21-04391">168</xref>]. See <xref ref-type="table" rid="ijms-21-04391-t002">Table 2</xref> for details about their mechanism of action. <xref ref-type="fig" rid="ijms-21-04391-f005">Figure 5</xref> shows the molecular pathways targeted by curcumin and piperine in preclinical studies. There is no cure for FXTAS and none of the drugs mentioned previously provide enough evidence for their clinical use in FXTAS. There is a need for continuing clinical trials in the search for a targeted treatment. Current management of FXTAS focuses on supportive and symptomatic treatment.</p>
</sec>
<sec id="sec8-ijms-21-04391" sec-type="conclusions">
<title>8. Conclusions</title>
<p>FXTAS is a neurodegenerative disorder that presents mainly as intention tremor and/or ataxia with cognitive decline, neuropathy, and autonomic dysfunction. FXTAS occurs mostly in PM carriers. Given the high prevalence of PM alleles, it is likely that a clinician will encounter a patient who is a PM carrier. It is important to consider FXTAS in the differential diagnosis of adults presenting with movement disorders, especially if there is a family history consistent with FXS or premutation disorders such as FXPOI or FXAND. Clinicians who are unaware of the carrier status of their patients may misdiagnose FXTAS, and it is therefore important to perform a thorough family history and consider genetic testing for <italic>FMR1</italic> repeat expansion when indicated. There are currently no targeted treatments for FXTAS, but there are ongoing clinical trials. It is important for PM carriers to modify their lifestyle and prevent noxious environmental exposure in order to prevent or delay FXTAS symptoms.</p>
</sec>
</body>
<back>
<notes>
<title>Author Contributions</title>
<p>Conceptualization, R.J.H., A.M.C.-H., N.T. and M.J.S.-A.; writing—original draft preparation, R.J.H., A.M.C.-H., N.T., M.J.S.-A.; writing—review and editing, R.J.H., A.M.C.-H., N.T., M.J.S.-A. All authors have read and agreed to the published version of the manuscript.</p>
</notes>
<notes>
<title>Funding</title>
<p>This research received no external funding.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>R.J.H. has received funding from Zynerba, Ovid, and the Azrieli Foundation for treatment trials in FXS. R.J.H. has also consulted with Zynerba and Fulcrum regarding the organization of clinical trials in FXS. We also acknowledge funding from NICHD (HD036071) and the MIND Institute IDDRC funding from NICHD (U54 HD079125).</p>
</notes>
<glossary>
<title>Abbreviations</title>
<array orientation="portrait">
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">AD</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Alzheimer’s disease</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle"><italic>ASFMR1</italic>-TV2</td>
<td align="left" colspan="1" rowspan="1" valign="middle"><italic>antisense FMR1</italic> transcript/splice variant 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">DGCR8</td>
<td align="left" colspan="1" rowspan="1" valign="middle">DiGeorge Syndrome Critical Region 8</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">
<italic>FM</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Full mutation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">
<italic>FMR1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Fragile X Mental Retardation 1 gene</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">FMRP</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Fragile X Mental Retardation Protein</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">FXAND</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Fragile X-associated neuropsychiatric disorders</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">FXPOI</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Fragile X-associated primary ovarian insufficiency</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">FXTAS</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Fragile-X-associated tremor/ataxia syndrome</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">FXS</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Fragile X syndrome</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">hnRNP A2/B1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">heterogeneous nuclear ribonucleoproteins A2/B1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">HP1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">heterochromatin protein 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">LAP2β</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Lamina-associated polypeptide 2 beta</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">MCP</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Middle Cerebellar Peduncles</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">MRI</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Magnetic Resonance Images</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PD</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Parkinson’s disease</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PM</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Premutation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PSP</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Progressive supranuclear palsy</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Purα</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Pur-alpha</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">RANT</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Repeat associated non-AUG translation</td>
</tr>
</tbody>
</array>
</glossary>
<ref-list>
<title>References</title>
<ref id="B1-ijms-21-04391">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hazlett</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>D.B.</given-names>
</name>
<name>
<surname>Moine</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kooy</surname>
<given-names>R.F.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Gantois</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Sonenberg</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mandel</surname>
<given-names>J.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Fragile X syndrome</article-title>
<source/>Nat. Rev. Dis. Primers
          <year>2017</year>
<volume>3</volume>
<fpage>17065</fpage>
<pub-id pub-id-type="doi">10.1038/nrdp.2017.65</pub-id>
<pub-id pub-id-type="pmid">28960184</pub-id>
</element-citation>
</ref>
<ref id="B2-ijms-21-04391">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quartier</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Poquet</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gilbert-Dussardier</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Casteleyn</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Des Portes</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Feger</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nourisson</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kuentz</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Redin</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intragenic FMR1 disease-causing variants: A significant mutational mechanism leading to Fragile-X syndrome</article-title>
<source/>Eur. J. Hum. Genet.
          <year>2017</year>
<volume>25</volume>
<fpage>423</fpage>
<lpage>431</lpage>
<pub-id pub-id-type="doi">10.1038/ejhg.2016.204</pub-id>
<pub-id pub-id-type="pmid">28176767</pub-id>
</element-citation>
</ref>
<ref id="B3-ijms-21-04391">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Myrick</surname>
<given-names>L.K.</given-names>
</name>
<name>
<surname>Nakamoto-Kinoshita</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lindor</surname>
<given-names>N.M.</given-names>
</name>
<name>
<surname>Kirmani</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>S.T.</given-names>
</name>
</person-group>
<article-title>Fragile X syndrome due to a missense mutation</article-title>
<source/>Eur. J. Hum. Genet.
          <year>2014</year>
<volume>22</volume>
<fpage>1185</fpage>
<lpage>1189</lpage>
<pub-id pub-id-type="doi">10.1038/ejhg.2013.311</pub-id>
<pub-id pub-id-type="pmid">24448548</pub-id>
</element-citation>
</ref>
<ref id="B4-ijms-21-04391">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sidorov</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Auerbach</surname>
<given-names>B.D.</given-names>
</name>
<name>
<surname>Bear</surname>
<given-names>M.F.</given-names>
</name>
</person-group>
<article-title>Fragile X mental retardation protein and synaptic plasticity</article-title>
<source/>Mol. Brain
          <year>2013</year>
<volume>6</volume>
<fpage>1</fpage>
<pub-id pub-id-type="doi">10.1186/1756-6606-6-15</pub-id>
<pub-id pub-id-type="pmid">23281934</pub-id>
</element-citation>
</ref>
<ref id="B5-ijms-21-04391">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huber</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Gallagher</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>S.T.</given-names>
</name>
<name>
<surname>Bear</surname>
<given-names>M.F.</given-names>
</name>
</person-group>
<article-title>Altered synaptic plasticity in a mouse model of fragile X mental retardation</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2002</year>
<volume>99</volume>
<fpage>7746</fpage>
<lpage>7750</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.122205699</pub-id>
<pub-id pub-id-type="pmid">12032354</pub-id>
</element-citation>
</ref>
<ref id="B6-ijms-21-04391">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sunamura</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Iwashita</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Enomoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kadoshima</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Isono</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Loss of the fragile X mental retardation protein causes aberrant differentiation in human neural progenitor cells</article-title>
<source/>Sci. Rep.
          <year>2018</year>
<volume>8</volume>
<fpage>11585</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-018-30025-4</pub-id>
<pub-id pub-id-type="pmid">30072797</pub-id>
</element-citation>
</ref>
<ref id="B7-ijms-21-04391">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monaghan</surname>
<given-names>K.G.</given-names>
</name>
<name>
<surname>Lyon</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Spector</surname>
<given-names>E.B.</given-names>
</name>
</person-group>
<article-title>ACMG standards and guidelines for fragile X testing: A revision to the disease-specific supplements to the standards and guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics and Genomics</article-title>
<source/>Genet. Med.
          <year>2013</year>
<volume>15</volume>
<fpage>575</fpage>
<lpage>586</lpage>
<pub-id pub-id-type="doi">10.1038/gim.2013.61</pub-id>
<pub-id pub-id-type="pmid">23765048</pub-id>
</element-citation>
</ref>
<ref id="B8-ijms-21-04391">
<label>8.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Sherman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>E.G.</given-names>
</name>
<name>
<surname>Jesica</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Clinical manifestation and management of FXPOI</article-title>
<source/>FXTAS, FXPOI, and Other Premutation Disorders
          <person-group person-group-type="editor">
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<publisher-name>Springer Nature</publisher-name>
<publisher-loc>Basel, Switzerland</publisher-loc>
<year>2016</year>
<fpage>199</fpage>
<lpage>224</lpage>
<isbn>978-3-319-33896-5</isbn>
</element-citation>
</ref>
<ref id="B9-ijms-21-04391">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Protic</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rajaratnam</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Salcedo-Arellano</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Aydin</surname>
<given-names>E.Y.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Fragile X-Associated Neuropsychiatric Disorders (FXAND)</article-title>
<source/>Front. Psychiatry
          <year>2018</year>
<volume>9</volume>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.3389/fpsyt.2018.00564</pub-id>
<pub-id pub-id-type="pmid">29410632</pub-id>
</element-citation>
</ref>
<ref id="B10-ijms-21-04391">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salcedo-Arellano</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Martinez-Cerdeno</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Fragile X associated tremor/ataxia syndrome: Its clinical presentation, pathology, and treatment TT—Sindrome de temblor y ataxia asociado al X fragil: Presentacion clinica, patologia y tratamiento</article-title>
<source/>Rev. Neurol.
          <year>2019</year>
<volume>68</volume>
<fpage>199</fpage>
<lpage>206</lpage>
<pub-id pub-id-type="pmid">30805918</pub-id>
</element-citation>
</ref>
<ref id="B11-ijms-21-04391">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Heinrichs</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hills</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Grigsby</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gage</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X</article-title>
<source/>Neurology
          <year>2001</year>
<volume>57</volume>
<fpage>127</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.57.1.127</pub-id>
<pub-id pub-id-type="pmid">11445641</pub-id>
</element-citation>
</ref>
<ref id="B12-ijms-21-04391">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Fragile X-associated tremor/ataxia syndrome—Features, mechanisms and management</article-title>
<source/>Nat. Rev. Neurol.
          <year>2016</year>
<volume>12</volume>
<fpage>403</fpage>
<lpage>412</lpage>
<pub-id pub-id-type="doi">10.1038/nrneurol.2016.82</pub-id>
<pub-id pub-id-type="pmid">27340021</pub-id>
</element-citation>
</ref>
<ref id="B13-ijms-21-04391">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Winarni</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Fragile X-associated tremor/ataxia syndrome (FXTAS) in grey zone carriers</article-title>
<source/>Clin. Genet.
          <year>2013</year>
<volume>84</volume>
<fpage>74</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="doi">10.1111/cge.12026</pub-id>
<pub-id pub-id-type="pmid">23009394</pub-id>
</element-citation>
</ref>
<ref id="B14-ijms-21-04391">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Klepitskaya</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Fragile X–associated tremor ataxia syndrome in FMR1 gray zone allele carriers</article-title>
<source/>Mov. Disord.
          <year>2012</year>
<volume>27</volume>
<fpage>297</fpage>
<lpage>301</lpage>
<pub-id pub-id-type="doi">10.1002/mds.24021</pub-id>
</element-citation>
</ref>
<ref id="B15-ijms-21-04391">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santa María</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pugin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alliende</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Aliaga</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Curotto</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Aravena</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>H.-T.</given-names>
</name>
<name>
<surname>Mendoza-Morales</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>FXTAS in an unmethylated mosaic male with fragile X syndrome from Chile</article-title>
<source/>Clin. Genet.
          <year>2014</year>
<volume>86</volume>
<fpage>378</fpage>
<lpage>382</lpage>
<pub-id pub-id-type="doi">10.1111/cge.12278</pub-id>
<pub-id pub-id-type="pmid">24028275</pub-id>
</element-citation>
</ref>
<ref id="B16-ijms-21-04391">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loesch</surname>
<given-names>D.Z.</given-names>
</name>
<name>
<surname>Sherwell</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kinsella</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Amor</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sung</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Fragile X-associated tremor/ataxia phenotype in a male carrier of unmethylated full mutation in the FMR1 gene</article-title>
<source/>Clin. Genet.
          <year>2012</year>
<volume>82</volume>
<fpage>88</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="doi">10.1111/j.1399-0004.2011.01675.x</pub-id>
<pub-id pub-id-type="pmid">21476992</pub-id>
</element-citation>
</ref>
<ref id="B17-ijms-21-04391">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pretto</surname>
<given-names>D.I.</given-names>
</name>
<name>
<surname>Hunsaker</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Cunningham</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Greco</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Noctor</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Intranuclear inclusions in a fragile X mosaic male</article-title>
<source/>Transl. Neurodegener.
          <year>2013</year>
<volume>2</volume>
<fpage>10</fpage>
<pub-id pub-id-type="doi">10.1186/2047-9158-2-10</pub-id>
<pub-id pub-id-type="pmid">23692864</pub-id>
</element-citation>
</ref>
<ref id="B18-ijms-21-04391">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacquemont</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Grigsby</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Brunberg</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Greco</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Des Portes</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Jardini</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Fragile X premutation tremor/ataxia syndrome: Molecular, clinical, and neuroimaging correlates</article-title>
<source/>Am. J. Hum. Genet.
          <year>2003</year>
<volume>72</volume>
<fpage>869</fpage>
<lpage>878</lpage>
<pub-id pub-id-type="doi">10.1086/374321</pub-id>
<pub-id pub-id-type="pmid">12638084</pub-id>
</element-citation>
</ref>
<ref id="B19-ijms-21-04391">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hunter</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rivero-Arias</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Angelov</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Fotheringham</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Leal</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Epidemiology of fragile X syndrome: A systematic review and meta-analysis</article-title>
<source/>Am. J. Med. Genet. Part A
          <year>2014</year>
<volume>164</volume>
<fpage>1648</fpage>
<lpage>1658</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.36511</pub-id>
</element-citation>
</ref>
<ref id="B20-ijms-21-04391">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saldarriaga</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Forero-Forero</surname>
<given-names>J.V.</given-names>
</name>
<name>
<surname>González-Teshima</surname>
<given-names>L.Y.</given-names>
</name>
<name>
<surname>Fandiño-Losada</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Isaza</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tovar-Cuevas</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Choudhary</surname>
<given-names>N.S.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>H.T.</given-names>
</name>
<name>
<surname>Aguilar-Gaxiola</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic cluster of fragile X syndrome in a Colombian district</article-title>
<source/>J. Hum. Genet.
          <year>2018</year>
<volume>63</volume>
<fpage>509</fpage>
<lpage>516</lpage>
<pub-id pub-id-type="doi">10.1038/s10038-017-0407-6</pub-id>
<pub-id pub-id-type="pmid">29379191</pub-id>
</element-citation>
</ref>
<ref id="B21-ijms-21-04391">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Otsuka</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sakamoto</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Siomi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Itakura</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Matumoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nanba</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Fragile X carrier screening and FMR1 allele distribution in the Japanese population</article-title>
<source/>Brain Dev.
          <year>2010</year>
<volume>32</volume>
<fpage>110</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="doi">10.1016/j.braindev.2008.12.015</pub-id>
<pub-id pub-id-type="pmid">19211207</pub-id>
</element-citation>
</ref>
<ref id="B22-ijms-21-04391">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacquemont</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Brunberg</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Jardini</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Gane</surname>
<given-names>L.W.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Herman</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Penetrance of the Fragile X—Associated Tremor / Ataxia Syndrome in a Premutation Carrier Population</article-title>
<source/>JAMA
          <year>2004</year>
<volume>291</volume>
<fpage>10</fpage>
<pub-id pub-id-type="doi">10.1001/jama.291.4.460</pub-id>
<pub-id pub-id-type="pmid">14747503</pub-id>
</element-citation>
</ref>
<ref id="B23-ijms-21-04391">
<label>23.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mailick</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The epidemiology of FXTAS</article-title>
<source/>FXTAS, FXPOI, and Other Premutation Disorders
          <person-group person-group-type="editor">
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
</person-group>
<publisher-name>Springer Nature</publisher-name>
<publisher-loc>Basel, Switzerland</publisher-loc>
<year>2016</year>
<fpage>25</fpage>
<isbn>978-3-319-33898-9</isbn>
</element-citation>
</ref>
<ref id="B24-ijms-21-04391">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brussino</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gellera</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Saluto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mariotti</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Arduino</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Castellotti</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Camerlingo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>de Angelis</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Orsi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tosca</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FMR1 gene premutation is a frequent genetic cause of late-onset sporadic cerebellar ataxia</article-title>
<source/>Neurology
          <year>2005</year>
<volume>64</volume>
<fpage>145</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="doi">10.1212/01.WNL.0000148723.37489.3F</pub-id>
<pub-id pub-id-type="pmid">15642922</pub-id>
</element-citation>
</ref>
<ref id="B25-ijms-21-04391">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Esch</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Dom</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bex</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Salden</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Caeckebeke</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wibail</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Borghgraef</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Legius</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Fryns</surname>
<given-names>J.-P.</given-names>
</name>
<name>
<surname>Matthijs</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Screening for FMR-1 premutations in 122 older Flemish males presenting with ataxia</article-title>
<source/>Eur. J. Hum. Genet.
          <year>2005</year>
<volume>13</volume>
<fpage>121</fpage>
<lpage>123</lpage>
<pub-id pub-id-type="doi">10.1038/sj.ejhg.5201312</pub-id>
<pub-id pub-id-type="pmid">15483640</pub-id>
</element-citation>
</ref>
<ref id="B26-ijms-21-04391">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adams</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Steenblock</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Thibodeau</surname>
<given-names>S.N.</given-names>
</name>
<name>
<surname>Lindor</surname>
<given-names>N.M.</given-names>
</name>
</person-group>
<article-title>Premutations in the FMR1 Gene Are Uncommon in Men Undergoing Genetic Testing for Spinocerebellar Ataxia</article-title>
<source/>J. Neurogenet.
          <year>2008</year>
<volume>22</volume>
<fpage>77</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="doi">10.1080/01677060701686242</pub-id>
<pub-id pub-id-type="pmid">18363164</pub-id>
</element-citation>
</ref>
<ref id="B27-ijms-21-04391">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Biancalana</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Toft</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Le Ber</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Tison</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Scherrer</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Thibodeau</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mandel</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Brice</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Farrer</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Dürr</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>FMR1 Premutations Associated With Fragile X–Associated Tremor/Ataxia Syndrome in Multiple System Atrophy</article-title>
<source/>Arch. Neurol.
          <year>2005</year>
<volume>62</volume>
<fpage>962</fpage>
<lpage>966</lpage>
<pub-id pub-id-type="doi">10.1001/archneur.62.6.962</pub-id>
<pub-id pub-id-type="pmid">15956167</pub-id>
</element-citation>
</ref>
<ref id="B28-ijms-21-04391">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garland</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Vnencak-Jones</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Biaggioni</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>T.L.</given-names>
</name>
<name>
<surname>Montine</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Fragile X gene premutation in multiple system atrophy</article-title>
<source/>J. Neurol. Sci.
          <year>2004</year>
<volume>227</volume>
<fpage>115</fpage>
<lpage>118</lpage>
<pub-id pub-id-type="doi">10.1016/j.jns.2004.08.013</pub-id>
<pub-id pub-id-type="pmid">15546601</pub-id>
</element-citation>
</ref>
<ref id="B29-ijms-21-04391">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yabe</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Soma</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Takei</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fujik</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>No association between FMR1 premutations and multiple system atrophy</article-title>
<source/>J. Neurol.
          <year>2004</year>
<volume>251</volume>
<fpage>1411</fpage>
<lpage>1412</lpage>
<pub-id pub-id-type="doi">10.1007/s00415-004-0546-5</pub-id>
<pub-id pub-id-type="pmid">15592742</pub-id>
</element-citation>
</ref>
<ref id="B30-ijms-21-04391">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kraff</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>H.-T.</given-names>
</name>
<name>
<surname>Cilia</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Canesi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pezzoli</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Goldwurm</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Screen for Excess FMR1 Premutation Alleles Among Males With Parkinsonism</article-title>
<source/>Arch. Neurol.
          <year>2007</year>
<volume>64</volume>
<fpage>1002</fpage>
<lpage>1006</lpage>
<pub-id pub-id-type="doi">10.1001/archneur.64.7.1002</pub-id>
<pub-id pub-id-type="pmid">17620491</pub-id>
</element-citation>
</ref>
<ref id="B31-ijms-21-04391">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cilia</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kraff</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Canesi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pezzoli</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Goldwurm</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Amiri</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>H.-T.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Screening for the Presence of FMR1 Premutation Alleles in Women With Parkinsonism</article-title>
<source/>Arch. Neurol.
          <year>2009</year>
<volume>66</volume>
<fpage>244</fpage>
<lpage>249</lpage>
<pub-id pub-id-type="doi">10.1001/archneurol.2008.548</pub-id>
<pub-id pub-id-type="pmid">19204162</pub-id>
</element-citation>
</ref>
<ref id="B32-ijms-21-04391">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Spector</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Zerbe</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Ouyang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>FMR1 gray-zone alleles: Association with Parkinson’s disease in women?</article-title>
<source/>Mov. Disord.
          <year>2011</year>
<volume>26</volume>
<fpage>1900</fpage>
<lpage>1906</lpage>
<pub-id pub-id-type="doi">10.1002/mds.23755</pub-id>
<pub-id pub-id-type="pmid">21567456</pub-id>
</element-citation>
</ref>
<ref id="B33-ijms-21-04391">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia Arocena</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Louis</surname>
<given-names>E.D.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Gilliam</surname>
<given-names>T.C.</given-names>
</name>
<name>
<surname>Ottman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jacquemont</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>Screen for expanded FMR1 alleles in patients with essential tremor</article-title>
<source/>Mov. Disord.
          <year>2004</year>
<volume>19</volume>
<fpage>930</fpage>
<lpage>933</lpage>
<pub-id pub-id-type="doi">10.1002/mds.20043</pub-id>
<pub-id pub-id-type="pmid">15300658</pub-id>
</element-citation>
</ref>
<ref id="B34-ijms-21-04391">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>J.-H.</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Youn</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ki</surname>
<given-names>C.-S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H.-T.</given-names>
</name>
<name>
<surname>Louis</surname>
<given-names>E.D.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>J.W.</given-names>
</name>
</person-group>
<article-title>Prevalence of fragile X-associated tremor/ataxia syndrome: A survey of essential tremor patients with cerebellar signs or extrapyramidal signs</article-title>
<source/>Brain Behav.
          <year>2019</year>
<volume>9</volume>
<fpage>e01337</fpage>
<pub-id pub-id-type="doi">10.1002/brb3.1337</pub-id>
<pub-id pub-id-type="pmid">31158927</pub-id>
</element-citation>
</ref>
<ref id="B35-ijms-21-04391">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clark</surname>
<given-names>L.N.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Louis</surname>
<given-names>E.D.</given-names>
</name>
</person-group>
<article-title>Genetic analysis of FMR1 repeat expansion in essential tremor</article-title>
<source/>Neurosci. Lett.
          <year>2015</year>
<volume>593</volume>
<fpage>114</fpage>
<lpage>117</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2015.03.027</pub-id>
<pub-id pub-id-type="pmid">25796179</pub-id>
</element-citation>
</ref>
<ref id="B36-ijms-21-04391">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>O’Keefe</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Fragile x-associated tremor ataxia syndrome: The expanding clinical picture, pathophysiology, epidemiology, and update on treatment</article-title>
<source/>Tremor Other Hyperkinetic Mov.
          <year>2012</year>
<volume>2</volume>
<fpage>2</fpage>
</element-citation>
</ref>
<ref id="B37-ijms-21-04391">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Jacquemont</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Cogswell</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Initial diagnoses given to persons with the fragile X associated tremor/ataxia syndrome (FXTAS)</article-title>
<source/>Neurology
          <year>2005</year>
<volume>65</volume>
<fpage>299</fpage>
<lpage>301</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000168900.86323.9c</pub-id>
<pub-id pub-id-type="pmid">16043804</pub-id>
</element-citation>
</ref>
<ref id="B38-ijms-21-04391">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grigsby</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>The fragile X mental retardation 1 gene (FMR1): Historical perspective, phenotypes, mechanism, pathology, and epidemiology</article-title>
<source/>Clin. Neuropsychol.
          <year>2016</year>
<volume>30</volume>
<fpage>815</fpage>
<lpage>833</lpage>
<pub-id pub-id-type="doi">10.1080/13854046.2016.1184652</pub-id>
<pub-id pub-id-type="pmid">27356167</pub-id>
</element-citation>
</ref>
<ref id="B39-ijms-21-04391">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodriguez-Revenga</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Madrigal</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Pagonabarraga</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xunclà</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Badenas</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kulisevsky</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gomez</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Milà</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families</article-title>
<source/>Eur. J. Hum. Genet.
          <year>2009</year>
<volume>17</volume>
<fpage>1359</fpage>
<lpage>1362</lpage>
<pub-id pub-id-type="doi">10.1038/ejhg.2009.51</pub-id>
<pub-id pub-id-type="pmid">19367323</pub-id>
</element-citation>
</ref>
<ref id="B40-ijms-21-04391">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leehey</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Goetz</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Lara</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cogswell</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FMR1 CGG repeat length predicts motor dysfunction in premutation carriers</article-title>
<source/>Neurology
          <year>2008</year>
<volume>70</volume>
<fpage>1397</fpage>
<lpage>1402</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000281692.98200.f5</pub-id>
<pub-id pub-id-type="pmid">18057320</pub-id>
</element-citation>
</ref>
<ref id="B41-ijms-21-04391">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Brusco</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>CGG repeat length correlates with age of onset of motor signs of the fragile X-associated tremor/ataxia syndrome (FXTAS)</article-title>
<source/>Am. J. Med. Genet. Part B Neuropsychiatr. Genet.
          <year>2007</year>
<volume>144</volume>
<fpage>566</fpage>
<lpage>569</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.30482</pub-id>
</element-citation>
</ref>
<ref id="B42-ijms-21-04391">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leehey</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Min</surname>
<given-names>S.-J.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Grigsby</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Greco</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lara</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Progression of tremor and ataxia in male carriers of the FMR1 premutation</article-title>
<source/>Mov. Disord.
          <year>2007</year>
<volume>22</volume>
<fpage>203</fpage>
<lpage>206</lpage>
<pub-id pub-id-type="doi">10.1002/mds.21252</pub-id>
<pub-id pub-id-type="pmid">17133502</pub-id>
</element-citation>
</ref>
<ref id="B43-ijms-21-04391">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paul</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pessah</surname>
<given-names>I.N.</given-names>
</name>
<name>
<surname>Gane</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ono</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Brunberg</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bourgeois</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>P.E.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>D.V.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Early onset of neurological symptoms in fragile X premutation carriers exposed to neurotoxins</article-title>
<source/>Neurotoxicology
          <year>2010</year>
<volume>31</volume>
<fpage>399</fpage>
<lpage>402</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuro.2010.04.002</pub-id>
<pub-id pub-id-type="pmid">20466021</pub-id>
</element-citation>
</ref>
<ref id="B44-ijms-21-04391">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martínez-Cerdeño</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Lechpammer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lott</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Fragile X-associated tremor/ataxia syndrome in a man in his 30s</article-title>
<source/>JAMA Neurol.
          <year>2015</year>
<volume>72</volume>
<fpage>1070</fpage>
<lpage>1073</lpage>
<pub-id pub-id-type="doi">10.1001/jamaneurol.2015.1138</pub-id>
<pub-id pub-id-type="pmid">26368352</pub-id>
</element-citation>
</ref>
<ref id="B45-ijms-21-04391">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muzar</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>P.E.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Lozano</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Addictive substances may induce a rapid neurological deterioration in fragile X-associated tremor ataxia syndrome: A report of two cases</article-title>
<source/>Intractable Rare Dis. Res.
          <year>2014</year>
<volume>3</volume>
<fpage>162</fpage>
<lpage>165</lpage>
<pub-id pub-id-type="doi">10.5582/irdr.2014.01023</pub-id>
<pub-id pub-id-type="pmid">25606366</pub-id>
</element-citation>
</ref>
<ref id="B46-ijms-21-04391">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saldarriaga</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Salcedo-Arellano</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Rodriguez-Guerrero</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ríos</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fandiño-Losada</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ramirez-Cheyne</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lein</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Increased severity of fragile X spectrum disorders in the agricultural community of Ricaurte, Colombia</article-title>
<source/>Int. J. Dev. Neurosci.
          <year>2019</year>
<volume>72</volume>
<fpage>1</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijdevneu.2018.10.002</pub-id>
<pub-id pub-id-type="pmid">30385191</pub-id>
</element-citation>
</ref>
<ref id="B47-ijms-21-04391">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Shelton</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Losh</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Mila</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Moreno</surname>
<given-names>E.G.</given-names>
</name>
<name>
<surname>Gomez-Anson</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Martínez-Cerdeño</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Grigsby</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lozano</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Update on the Clinical, Radiographic, and Neurobehavioral Manifestations in FXTAS and FMR1 Premutation Carriers</article-title>
<source/>Cerebellum
          <year>2016</year>
<volume>15</volume>
<fpage>578</fpage>
<lpage>586</lpage>
<pub-id pub-id-type="doi">10.1007/s12311-016-0799-4</pub-id>
<pub-id pub-id-type="pmid">27287737</pub-id>
</element-citation>
</ref>
<ref id="B48-ijms-21-04391">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gokden</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Al-Hinti</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Harik</surname>
<given-names>S.I.</given-names>
</name>
</person-group>
<article-title>Peripheral nervous system pathology in fragile X tremor/ataxia syndrome (FXTAS)</article-title>
<source/>Neuropathology
          <year>2009</year>
<volume>29</volume>
<fpage>280</fpage>
<lpage>284</lpage>
<pub-id pub-id-type="doi">10.1111/j.1440-1789.2008.00948.x</pub-id>
<pub-id pub-id-type="pmid">18627480</pub-id>
</element-citation>
</ref>
<ref id="B49-ijms-21-04391">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Herren</surname>
<given-names>A.W.</given-names>
</name>
<name>
<surname>Espinal</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Randol</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>McLaughlin</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Martinez-Cerdeño</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Pessah</surname>
<given-names>I.N.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS)</article-title>
<source/>Brain
          <year>2005</year>
<volume>129</volume>
<fpage>243</fpage>
<lpage>255</lpage>
<pub-id pub-id-type="pmid">16332642</pub-id>
</element-citation>
</ref>
<ref id="B50-ijms-21-04391">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamlin</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Sukharev</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Campos</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hessl</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>D.V.</given-names>
</name>
<name>
<surname>Loesch</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Hypertension in FMR1 premutation males with and without fragile X-associated tremor/ataxia syndrome (FXTAS)</article-title>
<source/>Am. J. Med. Genet. Part A
          <year>2012</year>
<volume>158</volume>
<fpage>1304</fpage>
<lpage>1309</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.35323</pub-id>
</element-citation>
</ref>
<ref id="B51-ijms-21-04391">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coffey</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tartaglia</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>D.V.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bronsky</surname>
<given-names>H.E.</given-names>
</name>
<name>
<surname>Yuhas</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Borodyanskaya</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Grigsby</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Expanded clinical phenotype of women with the FMR1 premutation</article-title>
<source/>Am. J. Med. Genet. Part A
          <year>2008</year>
<volume>146</volume>
<fpage>1009</fpage>
<lpage>1016</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.32060</pub-id>
</element-citation>
</ref>
<ref id="B52-ijms-21-04391">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamlin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>D.V.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Sleep apnea in fragile X premutation carriers with and without FXTAS</article-title>
<source/>Am. J. Med. Genet. Part B Neuropsychiatr. Genet.
          <year>2011</year>
<volume>156</volume>
<fpage>923</fpage>
<lpage>928</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.31237</pub-id>
</element-citation>
</ref>
<ref id="B53-ijms-21-04391">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Summers</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Cogswell</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Goodrich</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>D.V.</given-names>
</name>
<name>
<surname>Brass</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Prevalence of restless legs syndrome and sleep quality in carriers of the fragile X premutation</article-title>
<source/>Clin. Genet.
          <year>2014</year>
<volume>86</volume>
<fpage>181</fpage>
<lpage>184</lpage>
<pub-id pub-id-type="doi">10.1111/cge.12249</pub-id>
<pub-id pub-id-type="pmid">25180401</pub-id>
</element-citation>
</ref>
<ref id="B54-ijms-21-04391">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Au</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Akins</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Berkowitz-Sutherland</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>H.-T.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Boyd</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>D.V.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Prevalence and risk of migraine headaches in adult fragile X premutation carriers</article-title>
<source/>Clin. Genet.
          <year>2013</year>
<volume>84</volume>
<fpage>546</fpage>
<lpage>551</lpage>
<pub-id pub-id-type="doi">10.1111/cge.12109</pub-id>
<pub-id pub-id-type="pmid">23373759</pub-id>
</element-citation>
</ref>
<ref id="B55-ijms-21-04391">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wheeler</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>D.B.</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Losh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mailick</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Milà</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Olichney</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Rodriguez-Revenga</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sherman</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Associated features in females with an FMR1 premutation</article-title>
<source/>J. Neurodev. Disord.
          <year>2014</year>
<volume>6</volume>
<fpage>18</fpage>
<pub-id pub-id-type="doi">10.1186/1866-1955-6-30</pub-id>
<pub-id pub-id-type="pmid">25057328</pub-id>
</element-citation>
</ref>
<ref id="B56-ijms-21-04391">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Juncos</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Lazarus</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Graves-Allen</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Shubeck</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rusin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Novak</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rohr</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sherman</surname>
<given-names>S.L.</given-names>
</name>
</person-group>
<article-title>New clinical findings in the fragile X-associated tremor ataxia syndrome (FXTAS)</article-title>
<source/>Neurogenetics
          <year>2011</year>
<volume>12</volume>
<fpage>123</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="doi">10.1007/s10048-010-0270-5</pub-id>
<pub-id pub-id-type="pmid">21279400</pub-id>
</element-citation>
</ref>
<ref id="B57-ijms-21-04391">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Juncos</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Lazarus</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Rohr</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>E.G.</given-names>
</name>
<name>
<surname>Shubeck</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Novak</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sherman</surname>
<given-names>S.L.</given-names>
</name>
</person-group>
<article-title>Olfactory dysfunction in fragile X tremor ataxia syndrome</article-title>
<source/>Mov. Disord.
          <year>2012</year>
<volume>27</volume>
<fpage>1556</fpage>
<lpage>1559</lpage>
<pub-id pub-id-type="doi">10.1002/mds.25043</pub-id>
<pub-id pub-id-type="pmid">23079771</pub-id>
</element-citation>
</ref>
<ref id="B58-ijms-21-04391">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Summers</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Cogswell</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Goodrich</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>D.V.</given-names>
</name>
<name>
<surname>Brass</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Fatigue and body mass index in the Fragile X premutation carrier</article-title>
<source/>Fatigue Biomed. Health Behav.
          <year>2014</year>
<volume>2</volume>
<fpage>64</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="doi">10.1080/21641846.2014.881155</pub-id>
</element-citation>
</ref>
<ref id="B59-ijms-21-04391">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnston</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Eliez</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dyer-Friedman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hessl</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Glaser</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Blasey</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Reiss</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Neurobehavioral phenotype in carriers of the fragile X premutation</article-title>
<source/>Am. J. Med. Genet.
          <year>2001</year>
<volume>103</volume>
<fpage>314</fpage>
<lpage>319</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.1561</pub-id>
<pub-id pub-id-type="pmid">11746012</pub-id>
</element-citation>
</ref>
<ref id="B60-ijms-21-04391">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bourgeois</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Cogswell</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Hessl</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ono</surname>
<given-names>M.Y.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Farzin</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Brunberg</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Grigsby</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Cognitive, anxiety and mood disorders in the fragile X-associated tremor/ataxia syndrome</article-title>
<source/>Gen. Hosp. Psychiatry
          <year>2007</year>
<volume>29</volume>
<fpage>349</fpage>
<lpage>356</lpage>
<pub-id pub-id-type="doi">10.1016/j.genhosppsych.2007.03.003</pub-id>
<pub-id pub-id-type="pmid">17591512</pub-id>
</element-citation>
</ref>
<ref id="B61-ijms-21-04391">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bourgeois</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Seritan</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Casillas</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Hessl</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Cogswell</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>D.V.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers</article-title>
<source/>J. Clin. Psychiatry
          <year>2011</year>
<volume>72</volume>
<fpage>175</fpage>
<lpage>182</lpage>
<pub-id pub-id-type="doi">10.4088/JCP.09m05407blu</pub-id>
<pub-id pub-id-type="pmid">20816038</pub-id>
</element-citation>
</ref>
<ref id="B62-ijms-21-04391">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seritan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ortigas</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Seritan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bourgeois</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Psychiatric Disorders Associated with FXTAS</article-title>
<source/>Curr. Psychiatry Rev.
          <year>2013</year>
<volume>9</volume>
<fpage>59</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="pmid">25620899</pub-id>
</element-citation>
</ref>
<ref id="B63-ijms-21-04391">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leehey</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Legg</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Fibromyalgia in fragile X mental retardation 1 gene premutation carriers</article-title>
<source/>Rheumatology
          <year>2011</year>
<volume>50</volume>
<fpage>2233</fpage>
<lpage>2236</lpage>
<pub-id pub-id-type="doi">10.1093/rheumatology/ker273</pub-id>
<pub-id pub-id-type="pmid">21926154</pub-id>
</element-citation>
</ref>
<ref id="B64-ijms-21-04391">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Winarni</surname>
<given-names>T.I.</given-names>
</name>
<name>
<surname>Chonchaiya</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Sumekar</surname>
<given-names>T.A.</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Morales</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>D.V.</given-names>
</name>
<name>
<surname>Faradz</surname>
<given-names>S.M.H.</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Immune-mediated disorders among women carriers of fragile X premutation alleles</article-title>
<source/>Am. J. Med. Genet. Part A
          <year>2012</year>
<volume>158</volume>
<fpage>2473</fpage>
<lpage>2481</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.35569</pub-id>
<pub-id pub-id-type="pmid">22903889</pub-id>
</element-citation>
</ref>
<ref id="B65-ijms-21-04391">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seritan</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Benjamin</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Seritan</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Risk Factors for Cognitive Impairment in Fragile X-Associated Tremor/Ataxia Syndrome</article-title>
<source/>J. Geriatr. Psychiatry Neurol.
          <year>2016</year>
<volume>29</volume>
<fpage>328</fpage>
<lpage>337</lpage>
<pub-id pub-id-type="doi">10.1177/0891988716666379</pub-id>
<pub-id pub-id-type="pmid">27647792</pub-id>
</element-citation>
</ref>
<ref id="B66-ijms-21-04391">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Leavitt</surname>
<given-names>B.R.</given-names>
</name>
<name>
<surname>Farzin</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Jacquemont</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Greco</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Brunberg</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hessl</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Fragile-X–Associated Tremor/Ataxia Syndrome (FXTAS) in Females with the FMR1 Premutation</article-title>
<source/>Am. J. Hum. Genet.
          <year>2004</year>
<volume>74</volume>
<fpage>1051</fpage>
<lpage>1056</lpage>
<pub-id pub-id-type="doi">10.1086/420700</pub-id>
<pub-id pub-id-type="pmid">15065016</pub-id>
</element-citation>
</ref>
<ref id="B67-ijms-21-04391">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Greco</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Hunsaker</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Seritan</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Berman</surname>
<given-names>R.F.</given-names>
</name>
<name>
<surname>Gane</surname>
<given-names>L.W.</given-names>
</name>
<name>
<surname>Jacquemont</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Basuta</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>L.-W.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuropathological, clinical and molecular pathology in female fragile X premutation carriers with and without FXTAS</article-title>
<source/>Genes, Brain Behav.
          <year>2012</year>
<volume>11</volume>
<fpage>577</fpage>
<lpage>585</lpage>
<pub-id pub-id-type="doi">10.1111/j.1601-183X.2012.00779.x</pub-id>
<pub-id pub-id-type="pmid">22463693</pub-id>
</element-citation>
</ref>
<ref id="B68-ijms-21-04391">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Robertson-Dick</surname>
<given-names>E.E.</given-names>
</name>
<name>
<surname>Keefe</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Hadd</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>X-inactivation in the clinical phenotype of fragile X premutation carrier sisters</article-title>
<source/>Neurol. Genet.
          <year>2016</year>
<volume>2</volume>
<fpage>e45</fpage>
<pub-id pub-id-type="doi">10.1212/NXG.0000000000000045</pub-id>
<pub-id pub-id-type="pmid">27066582</pub-id>
</element-citation>
</ref>
<ref id="B69-ijms-21-04391">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alvarez-Mora</surname>
<given-names>M.I.</given-names>
</name>
<name>
<surname>Rodriguez-Revenga</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Feliu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Badenas</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Madrigal</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Milà</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Skewed X Inactivation in Women Carrying the <bold><italic>FMR1</italic></bold> Premutation and Its Relation with Fragile-X-Associated Tremor/Ataxia Syndrome</article-title>
<source/>Neurodegener. Dis.
          <year>2016</year>
<volume>16</volume>
<fpage>290</fpage>
<lpage>292</lpage>
<pub-id pub-id-type="doi">10.1159/000441566</pub-id>
<pub-id pub-id-type="pmid">26609701</pub-id>
</element-citation>
</ref>
<ref id="B70-ijms-21-04391">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vittal</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pandya</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sharp</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ouyang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>ASFMR1 splice variant: A predictor of fragile X-associated tremor/ataxia syndrome</article-title>
<source/>Neurol. Genet.
          <year>2018</year>
<volume>4</volume>
<fpage>e246</fpage>
<pub-id pub-id-type="doi">10.1212/NXG.0000000000000246</pub-id>
<pub-id pub-id-type="pmid">30065951</pub-id>
</element-citation>
</ref>
<ref id="B71-ijms-21-04391">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ligsay</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>El-Deeb</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Salcedo-Arellano</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Schloemerkemper</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Grayson</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>General Anesthetic Use in Fragile X Spectrum Disorders</article-title>
<source/>J. Neurosurg. Anesthesiol.
          <year>2019</year>
<volume>31</volume>
<fpage>285</fpage>
<lpage>290</lpage>
<pub-id pub-id-type="doi">10.1097/ANA.0000000000000508</pub-id>
<pub-id pub-id-type="pmid">29734272</pub-id>
</element-citation>
</ref>
<ref id="B72-ijms-21-04391">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Dwyer</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Clabby</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Crown</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Barton</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Hutchinson</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Fragile X-associated tremor/ataxia syndrome presenting in a woman after chemotherapy</article-title>
<source/>Neurology
          <year>2005</year>
<volume>65</volume>
<fpage>331</fpage>
<lpage>332</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000168865.36352.53</pub-id>
<pub-id pub-id-type="pmid">16043816</pub-id>
</element-citation>
</ref>
<ref id="B73-ijms-21-04391">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muzar</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Lozano</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>P.E.</given-names>
</name>
<name>
<surname>Faradz</surname>
<given-names>S.M.H.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Methadone use in a male with the FMRI premutation and FXTAS</article-title>
<source/>Am. J. Med. Genet. Part A
          <year>2015</year>
<volume>167</volume>
<fpage>1354</fpage>
<lpage>1359</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.37030</pub-id>
<pub-id pub-id-type="pmid">25900641</pub-id>
</element-citation>
</ref>
<ref id="B74-ijms-21-04391">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Deeb</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Salcedo-Arellano</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Fentanyl overdose in a female with the FMR1 premutation and FXTAS</article-title>
<source/>J. Mol. Genet.
          <year>2018</year>
<volume>1</volume>
<fpage>101</fpage>
</element-citation>
</ref>
<ref id="B75-ijms-21-04391">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greco</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Berman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Trapp</surname>
<given-names>B.D.</given-names>
</name>
<name>
<surname>Iwahashi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Brunberg</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Grigsby</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS)</article-title>
<source/>Brain
          <year>2006</year>
<volume>129</volume>
<fpage>243</fpage>
<lpage>255</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awh683</pub-id>
<pub-id pub-id-type="pmid">16332642</pub-id>
</element-citation>
</ref>
<ref id="B76-ijms-21-04391">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Apartis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Blancher</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Meissner</surname>
<given-names>W.G.</given-names>
</name>
<name>
<surname>Guyant-Maréchal</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Maltête</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>De Broucker</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Legrand</surname>
<given-names>A.-P.</given-names>
</name>
<name>
<surname>Bouzenada</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Thanh</surname>
<given-names>H.T.</given-names>
</name>
<name>
<surname>Sallansonnet-Froment</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FXTAS: New insights and the need for revised diagnostic criteria</article-title>
<source/>Neurology
          <year>2012</year>
<volume>79</volume>
<fpage>1898</fpage>
<lpage>1907</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0b013e318271f7ff</pub-id>
<pub-id pub-id-type="pmid">23077007</pub-id>
</element-citation>
</ref>
<ref id="B77-ijms-21-04391">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niu</surname>
<given-names>Y.-Q.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.-C.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Olichney</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Parkinsonism in fragile X-associated tremor/ataxia syndrome (FXTAS): Revisited</article-title>
<source/>Parkinsonism Relat. Disord.
          <year>2014</year>
<volume>20</volume>
<fpage>456</fpage>
<lpage>459</lpage>
<pub-id pub-id-type="doi">10.1016/j.parkreldis.2014.01.006</pub-id>
<pub-id pub-id-type="pmid">24491663</pub-id>
</element-citation>
</ref>
<ref id="B78-ijms-21-04391">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Keefe</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Robertson-Dick</surname>
<given-names>E.E.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Gait and Functional Mobility Deficits in Fragile X-Associated Tremor/Ataxia Syndrome</article-title>
<source/>Cerebellum
          <year>2016</year>
<volume>15</volume>
<fpage>475</fpage>
<lpage>482</lpage>
<pub-id pub-id-type="doi">10.1007/s12311-015-0714-4</pub-id>
<pub-id pub-id-type="pmid">26298472</pub-id>
</element-citation>
</ref>
<ref id="B79-ijms-21-04391">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Coffey</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Maselli</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Soontarapornchai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Brunberg</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gane</surname>
<given-names>L.W.</given-names>
</name>
<name>
<surname>Fenton-Farrell</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuropathy as a presenting feature in fragile X-associated tremor/ataxia syndrome</article-title>
<source/>Am. J. Med. Genet. Part A
          <year>2007</year>
<volume>143</volume>
<fpage>2256</fpage>
<lpage>2260</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.31920</pub-id>
</element-citation>
</ref>
<ref id="B80-ijms-21-04391">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chanson</surname>
<given-names>J.-B.</given-names>
</name>
<name>
<surname>Boehm</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Samama</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Echaniz-Laguna</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Anheim</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Small fiber neuropathy in a woman with fragile X-associated tremor/ataxia syndrome (FXTAS)</article-title>
<source/>J. Neurol.
          <year>2015</year>
<volume>262</volume>
<fpage>226</fpage>
<lpage>227</lpage>
<pub-id pub-id-type="doi">10.1007/s00415-014-7597-z</pub-id>
<pub-id pub-id-type="pmid">25488474</pub-id>
</element-citation>
</ref>
<ref id="B81-ijms-21-04391">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Goetz</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Tartaglia</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Cogswell</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuropathic features in fragile X premutation carriers</article-title>
<source/>Am. J. Med. Genet. Part A
          <year>2007</year>
<volume>143</volume>
<fpage>19</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.31559</pub-id>
</element-citation>
</ref>
<ref id="B82-ijms-21-04391">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fraint</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vittal</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Szewka</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bernard</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<article-title>New observations in the fragile X-associated tremor/ataxia syndrome (FXTAS) phenotype</article-title>
<source/>Front. Genet.
          <year>2014</year>
<volume>5</volume>
<fpage>365</fpage>
<pub-id pub-id-type="doi">10.3389/fgene.2014.00365</pub-id>
<pub-id pub-id-type="pmid">25368631</pub-id>
</element-citation>
</ref>
<ref id="B83-ijms-21-04391">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soontarapornchai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Maselli</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fenton-Farrell</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Hessl</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Abnormal Nerve Conduction Features in Fragile X Premutation Carriers</article-title>
<source/>Arch. Neurol.
          <year>2008</year>
<volume>65</volume>
<fpage>495</fpage>
<lpage>498</lpage>
<pub-id pub-id-type="doi">10.1001/archneur.65.4.495</pub-id>
<pub-id pub-id-type="pmid">18413472</pub-id>
</element-citation>
</ref>
<ref id="B84-ijms-21-04391">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hunsaker</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Greco</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Berman</surname>
<given-names>R.F.</given-names>
</name>
<name>
<surname>Willemsen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>Rare Intranuclear Inclusions in the Brains of 3 Older Adult Males With Fragile X Syndrome: Implications for the Spectrum of Fragile X-Associated Disorders</article-title>
<source/>J. Neuropathol. Exp. Neurol.
          <year>2011</year>
<volume>70</volume>
<fpage>462</fpage>
<lpage>469</lpage>
<pub-id pub-id-type="doi">10.1097/NEN.0b013e31821d3194</pub-id>
<pub-id pub-id-type="pmid">21572337</pub-id>
</element-citation>
</ref>
<ref id="B85-ijms-21-04391">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scaglione</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ginestroni</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vella</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dotti</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Della Nave</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rizzo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>De Cristofaro</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>De Stefano</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Piacentini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Martinelli</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>MRI and SPECT of midbrain and striatal degeneration in fragile X-associated tremor/ataxia syndrome</article-title>
<source/>J. Neurol.
          <year>2008</year>
<volume>255</volume>
<fpage>144</fpage>
<lpage>146</lpage>
<pub-id pub-id-type="doi">10.1007/s00415-007-0711-8</pub-id>
<pub-id pub-id-type="pmid">18080849</pub-id>
</element-citation>
</ref>
<ref id="B86-ijms-21-04391">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klusek</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sterling</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mailick</surname>
<given-names>M.R.</given-names>
</name>
</person-group>
<article-title>Inhibition deficits are modulated by age and CGG repeat length in carriers of the FMR1 premutation allele who are mothers of children with fragile X syndrome</article-title>
<source/>Brain Cogn.
          <year>2020</year>
<volume>139</volume>
<fpage>105511</fpage>
<pub-id pub-id-type="doi">10.1016/j.bandc.2019.105511</pub-id>
<pub-id pub-id-type="pmid">31887710</pub-id>
</element-citation>
</ref>
<ref id="B87-ijms-21-04391">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seritan</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>D.V.</given-names>
</name>
<name>
<surname>Farias</surname>
<given-names>S.T.</given-names>
</name>
<name>
<surname>Hinton</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Grigsby</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bourgeois</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Dementia in fragile X-associated tremor/ataxia syndrome (FXTAS): Comparison with Alzheimer’s disease</article-title>
<source/>Am. J. Med. Genet. Part B Neuropsychiatr. Genet.
          <year>2008</year>
<volume>147</volume>
<fpage>1138</fpage>
<lpage>1144</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.30732</pub-id>
</element-citation>
</ref>
<ref id="B88-ijms-21-04391">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grigsby</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Brega</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Jacquemont</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Loesch</surname>
<given-names>D.Z.</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Goodrich</surname>
<given-names>G.K.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Epstein</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cogswell</surname>
<given-names>J.B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Impairment in the cognitive functioning of men with fragile X-associated tremor/ataxia syndrome (FXTAS)</article-title>
<source/>J. Neurol. Sci.
          <year>2006</year>
<volume>248</volume>
<fpage>227</fpage>
<lpage>233</lpage>
<pub-id pub-id-type="doi">10.1016/j.jns.2006.05.016</pub-id>
<pub-id pub-id-type="pmid">16780889</pub-id>
</element-citation>
</ref>
<ref id="B89-ijms-21-04391">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grigsby</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Brega</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Goodrich</surname>
<given-names>G.K.</given-names>
</name>
<name>
<surname>Jacquemont</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Loesch</surname>
<given-names>D.Z.</given-names>
</name>
<name>
<surname>Cogswell</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Epstein</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jardini</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Impairment of executive cognitive functioning in males with fragile X-associated tremor/ataxia syndrome</article-title>
<source/>Mov. Disord.
          <year>2007</year>
<volume>22</volume>
<fpage>645</fpage>
<lpage>650</lpage>
<pub-id pub-id-type="doi">10.1002/mds.21359</pub-id>
<pub-id pub-id-type="pmid">17266074</pub-id>
</element-citation>
</ref>
<ref id="B90-ijms-21-04391">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grigsby</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Brega</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Engle</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hessl</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Cogswell</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>R.E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome</article-title>
<source/>Neuropsychology
          <year>2008</year>
<volume>22</volume>
<fpage>48</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="doi">10.1037/0894-4105.22.1.48</pub-id>
<pub-id pub-id-type="pmid">18211155</pub-id>
</element-citation>
</ref>
<ref id="B91-ijms-21-04391">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sévin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kutalik</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Bergman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vercelletto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Renou</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lamy</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Vingerhoets</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Di Virgilio</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Boisseau</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bezieau</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Penetrance of marked cognitive impairment in older male carriers of the &lt;em&gt;FMR1&lt;/em&gt; gene premutation</article-title>
<source/>J. Med. Genet.
          <year>2009</year>
<volume>46</volume>
<fpage>818</fpage>
<lpage>824</lpage>
<pub-id pub-id-type="pmid">19542082</pub-id>
</element-citation>
</ref>
<ref id="B92-ijms-21-04391">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Movaghar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mailick</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sterling</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Saha</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Automated screening for Fragile X premutation carriers based on linguistic and cognitive computational phenotypes</article-title>
<source/>Sci. Rep.
          <year>2017</year>
<volume>7</volume>
<fpage>2674</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-02682-4</pub-id>
<pub-id pub-id-type="pmid">28572606</pub-id>
</element-citation>
</ref>
<ref id="B93-ijms-21-04391">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nayar</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>McKinney</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Hogan</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>La Valle</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sharp</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Norton</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>P.C.</given-names>
</name>
<name>
<surname>Losh</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Language processing skills linked to FMR1 variation: A study of gaze-language coordination during rapid automatized naming among women with the FMR1 premutation</article-title>
<source/>PLoS ONE
          <year>2019</year>
<volume>14</volume>
<elocation-id>e0219924</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0219924</pub-id>
<pub-id pub-id-type="pmid">31348790</pub-id>
</element-citation>
</ref>
<ref id="B94-ijms-21-04391">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Keefe</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>E.E.</given-names>
</name>
<name>
<surname>Ouyang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Carns</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>McAsey</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Swanson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bernard</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<article-title>Cognitive function impacts gait, functional mobility and falls in fragile X-associated tremor/ataxia syndrome</article-title>
<source/>Gait Posture
          <year>2018</year>
<volume>66</volume>
<fpage>288</fpage>
<lpage>293</lpage>
<pub-id pub-id-type="doi">10.1016/j.gaitpost.2018.09.005</pub-id>
<pub-id pub-id-type="pmid">30243213</pub-id>
</element-citation>
</ref>
<ref id="B95-ijms-21-04391">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKenzie</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Tassanakijpanich</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Epps</surname>
<given-names>K.C.</given-names>
</name>
<name>
<surname>March</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Spontaneous Coronary Artery Dissection in Females With the Fragile X FMR1 Premutation</article-title>
<source/>JACC Case Rep.
          <year>2020</year>
<volume>2</volume>
<fpage>40</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaccas.2019.11.058</pub-id>
<pub-id pub-id-type="pmid">32154514</pub-id>
</element-citation>
</ref>
<ref id="B96-ijms-21-04391">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pugliese</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Annesi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cutuli</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Arabia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Nicoletti</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Annesi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tarantino</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gambardella</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Valentino</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zappia</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The fragile X premutation presenting as postprandial hypotension</article-title>
<source/>Neurology
          <year>2004</year>
<volume>63</volume>
<fpage>2188</fpage>
<lpage>2189</lpage>
<pub-id pub-id-type="doi">10.1212/01.WNL.0000145709.61117.08</pub-id>
</element-citation>
</ref>
<ref id="B97-ijms-21-04391">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Louis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Moskowitz</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Friez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Amaya</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vonsattel</surname>
<given-names>J.P.G.</given-names>
</name>
</person-group>
<article-title>Parkinsonism, dysautonomia, and intranuclear inclusions in a fragile X carrier: A clinical–pathological study</article-title>
<source/>Mov. Disord.
          <year>2006</year>
<volume>21</volume>
<fpage>420</fpage>
<lpage>425</lpage>
<pub-id pub-id-type="doi">10.1002/mds.20753</pub-id>
<pub-id pub-id-type="pmid">16250026</pub-id>
</element-citation>
</ref>
<ref id="B98-ijms-21-04391">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bacalman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Farzin</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bourgeois</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cogswell</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Goodlin-Jones</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Gane</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Grigsby</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Psychiatric Phenotype of the Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) in Males: Newly Described Fronto-Subcortical Dementia</article-title>
<source/>J. Clin. Psychiatry
          <year>2006</year>
<volume>67</volume>
<fpage>87</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.4088/JCP.v67n0112</pub-id>
<pub-id pub-id-type="pmid">16426093</pub-id>
</element-citation>
</ref>
<ref id="B99-ijms-21-04391">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Capelli</surname>
<given-names>L.P.</given-names>
</name>
<name>
<surname>Gonçalves</surname>
<given-names>M.R.R.</given-names>
</name>
<name>
<surname>Kok</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Leite</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Nitrini</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Barbosa</surname>
<given-names>E.R.</given-names>
</name>
<name>
<surname>Vianna-Morgante</surname>
<given-names>A.M.</given-names>
</name>
</person-group>
<article-title>Fragile X-associated tremor/ataxia syndrome: Intrafamilial variability and the size of the FMR1 premutation CGG repeat</article-title>
<source/>Mov. Disord.
          <year>2007</year>
<volume>22</volume>
<fpage>866</fpage>
<lpage>870</lpage>
<pub-id pub-id-type="doi">10.1002/mds.21347</pub-id>
<pub-id pub-id-type="pmid">17290448</pub-id>
</element-citation>
</ref>
<ref id="B100-ijms-21-04391">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loesch</surname>
<given-names>D.Z.</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Litewka</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gould</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Churchyard</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Slater</surname>
<given-names>H.R.</given-names>
</name>
<name>
<surname>Storey</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>A low symptomatic form of neurodegeneration in younger carriers of the FMR1 premutation, manifesting typical radiological changes</article-title>
<source/>J. Med. Genet.
          <year>2008</year>
<volume>45</volume>
<fpage>179</fpage>
<lpage>181</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2007.054171</pub-id>
<pub-id pub-id-type="pmid">18057083</pub-id>
</element-citation>
</ref>
<ref id="B101-ijms-21-04391">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Battistella</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Niederhauser</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fornari</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hippolyte</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gronchi Perrin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lesca</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Forzano</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hagmann</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Vingerhoets</surname>
<given-names>F.J.G.</given-names>
</name>
<name>
<surname>Draganski</surname>
<given-names>B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brain structure in asymptomatic FMR1 premutation carriers at risk for fragile X-associated tremor/ataxia syndrome</article-title>
<source/>Neurobiol. Aging
          <year>2013</year>
<volume>34</volume>
<fpage>1700</fpage>
<lpage>1707</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2012.12.001</pub-id>
<pub-id pub-id-type="pmid">23298734</pub-id>
</element-citation>
</ref>
<ref id="B102-ijms-21-04391">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Famula</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>McKenzie</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>McLennan</surname>
<given-names>Y.A.</given-names>
</name>
<name>
<surname>Grigsby</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hessl</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Martinez-Cerdeno</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Presence of middle cerebellar peduncle sign in FMR1 premutation carriers without tremor and ataxia</article-title>
<source/>Front. Neurol.
          <year>2018</year>
<volume>9</volume>
<fpage>1</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.3389/fneur.2018.00695</pub-id>
<pub-id pub-id-type="pmid">29403429</pub-id>
</element-citation>
</ref>
<ref id="B103-ijms-21-04391">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Renaud</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Perriard</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Coudray</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sévin-Allouet</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marcel</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Meissner</surname>
<given-names>W.G.</given-names>
</name>
<name>
<surname>Chanson</surname>
<given-names>J.-B.</given-names>
</name>
<name>
<surname>Collongues</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Philippi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Gebus</surname>
<given-names>O.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Relevance of corpus callosum splenium versus middle cerebellar peduncle hyperintensity for FXTAS diagnosis in clinical practice</article-title>
<source/>J. Neurol.
          <year>2015</year>
<volume>262</volume>
<fpage>435</fpage>
<lpage>442</lpage>
<pub-id pub-id-type="doi">10.1007/s00415-014-7557-7</pub-id>
<pub-id pub-id-type="pmid">25451852</pub-id>
</element-citation>
</ref>
<ref id="B104-ijms-21-04391">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adams</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>P.E.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Brunberg</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Koldewyn</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Grigsby</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Volumetric brain changes in females with fragile X-associated tremor/ataxia syndrome (FXTAS)</article-title>
<source/>Neurology
          <year>2007</year>
<volume>69</volume>
<fpage>851</fpage>
<lpage>859</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000269781.10417.7b</pub-id>
<pub-id pub-id-type="pmid">17724287</pub-id>
</element-citation>
</ref>
<ref id="B105-ijms-21-04391">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brunberg</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Jacquemont</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Grigsby</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>W.T.</given-names>
</name>
<name>
<surname>Greco</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>Fragile X Premutation Carriers: Characteristic MR Imaging Findings of Adult Male Patients with Progressive Cerebellar and Cognitive Dysfunction</article-title>
<source/>Am. J. Neuroradiol.
          <year>2002</year>
<volume>23</volume>
<fpage>1757</fpage>
<lpage>1766</lpage>
<pub-id pub-id-type="pmid">12427636</pub-id>
</element-citation>
</ref>
<ref id="B106-ijms-21-04391">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Javan</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>S.M.</given-names>
</name>
</person-group>
<article-title>A voxel-based morphometry study of grey matter loss in fragile X-associated tremor/ataxia syndrome</article-title>
<source/>Brain
          <year>2011</year>
<volume>134</volume>
<fpage>863</fpage>
<lpage>878</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awq368</pub-id>
<pub-id pub-id-type="pmid">21354978</pub-id>
</element-citation>
</ref>
<ref id="B107-ijms-21-04391">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>S.M.</given-names>
</name>
</person-group>
<article-title>A multimodal imaging analysis of subcortical gray matter in fragile X premutation carriers</article-title>
<source/>Mov. Disord.
          <year>2013</year>
<volume>28</volume>
<fpage>1278</fpage>
<lpage>1284</lpage>
<pub-id pub-id-type="doi">10.1002/mds.25473</pub-id>
<pub-id pub-id-type="pmid">23649693</pub-id>
</element-citation>
</ref>
<ref id="B108-ijms-21-04391">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Masyn</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hessl</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Brunberg</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>DeCarli</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cogswell</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Molecular and imaging correlates of the fragile X–associated tremor/ataxia syndrome</article-title>
<source/>Neurology
          <year>2006</year>
<volume>67</volume>
<fpage>1426</fpage>
<lpage>1431</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000239837.57475.3a</pub-id>
<pub-id pub-id-type="pmid">17060569</pub-id>
</element-citation>
</ref>
<ref id="B109-ijms-21-04391">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Hessl</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ferrer</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>S.M.</given-names>
</name>
</person-group>
<article-title>Abnormal trajectories in cerebellum and brainstem volumes in carriers of the fragile X premutation</article-title>
<source/>Neurobiol. Aging
          <year>2017</year>
<volume>55</volume>
<fpage>11</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2017.03.018</pub-id>
<pub-id pub-id-type="pmid">28391068</pub-id>
</element-citation>
</ref>
<ref id="B110-ijms-21-04391">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Hessl</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>S.M.</given-names>
</name>
</person-group>
<article-title>Interaction between ventricular expansion and structural changes in the corpus callosum and putamen in males with FMR1 normal and premutation alleles</article-title>
<source/>Neurobiol. Aging
          <year>2020</year>
<volume>86</volume>
<fpage>27</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2019.09.009</pub-id>
<pub-id pub-id-type="pmid">31733943</pub-id>
</element-citation>
</ref>
<ref id="B111-ijms-21-04391">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>S.M.</given-names>
</name>
</person-group>
<article-title>Diffusion tensor imaging in male premutation carriers of the fragile X mental retardation gene</article-title>
<source/>Mov. Disord.
          <year>2011</year>
<volume>26</volume>
<fpage>1329</fpage>
<lpage>1336</lpage>
<pub-id pub-id-type="doi">10.1002/mds.23646</pub-id>
<pub-id pub-id-type="pmid">21484870</pub-id>
</element-citation>
</ref>
<ref id="B112-ijms-21-04391">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Hessl</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Iwahashi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cheung</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>S.M.</given-names>
</name>
</person-group>
<article-title>Influence of the fragile X mental retardation (FMR1) gene on the brain and working memory in men with normal FMR1 alleles</article-title>
<source/>Neuroimage
          <year>2013</year>
<volume>65</volume>
<fpage>288</fpage>
<lpage>298</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroimage.2012.09.075</pub-id>
<pub-id pub-id-type="pmid">23063447</pub-id>
</element-citation>
</ref>
<ref id="B113-ijms-21-04391">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>S.S.G.</given-names>
</name>
<name>
<surname>Stanfield</surname>
<given-names>A.C.</given-names>
</name>
</person-group>
<article-title>Fragile X premutation carriers: A systematic review of neuroimaging findings</article-title>
<source/>J. Neurol. Sci.
          <year>2015</year>
<volume>352</volume>
<fpage>19</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="doi">10.1016/j.jns.2015.03.031</pub-id>
<pub-id pub-id-type="pmid">25847019</pub-id>
</element-citation>
</ref>
<ref id="B114-ijms-21-04391">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Hessl</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>S.M.</given-names>
</name>
</person-group>
<article-title>Fragile X–Associated Tremor/Ataxia Syndrome: Influence of the FMR1 Gene on Motor Fiber Tracts in Males With Normal and Premutation AllelesFragile X–Associated Tremor/Ataxia Syndrome</article-title>
<source/>JAMA Neurol.
          <year>2013</year>
<volume>70</volume>
<fpage>1022</fpage>
<lpage>1029</lpage>
<pub-id pub-id-type="doi">10.1001/jamaneurol.2013.2934</pub-id>
<pub-id pub-id-type="pmid">23753897</pub-id>
</element-citation>
</ref>
<ref id="B115-ijms-21-04391">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Birch</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Hocking</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Cornish</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Menant</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Georgiou-Karistianis</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Godler</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Hackett</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Trollor</surname>
<given-names>J.N.</given-names>
</name>
</person-group>
<article-title>Preliminary evidence of an effect of cerebellar volume on postural sway in FMR1 premutation males</article-title>
<source/>Genes Brain Behav.
          <year>2015</year>
<volume>14</volume>
<fpage>251</fpage>
<lpage>259</lpage>
<pub-id pub-id-type="doi">10.1111/gbb.12204</pub-id>
<pub-id pub-id-type="pmid">25689687</pub-id>
</element-citation>
</ref>
<ref id="B116-ijms-21-04391">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Backer</surname>
<given-names>K.C.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>S.M.</given-names>
</name>
</person-group>
<article-title>An fMRI study of the prefrontal activity during the performance of a working memory task in premutation carriers of the fragile X mental retardation 1 gene with and without fragile X-associated tremor/ataxia syndrome (FXTAS)</article-title>
<source/>J. Psychiatr. Res.
          <year>2011</year>
<volume>45</volume>
<fpage>36</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2010.04.030</pub-id>
<pub-id pub-id-type="pmid">20537351</pub-id>
</element-citation>
</ref>
<ref id="B117-ijms-21-04391">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hocking</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Loesch</surname>
<given-names>D.Z.</given-names>
</name>
<name>
<surname>Trost</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Bui</surname>
<given-names>M.Q.</given-names>
</name>
<name>
<surname>Hammersley</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Storey</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Total and regional white matter lesions are correlated with motor and cognitive impairments in carriers of the FMR1 premutation</article-title>
<source/>Front. Neurol.
          <year>2019</year>
<volume>10</volume>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.3389/fneur.2019.00832</pub-id>
<pub-id pub-id-type="pmid">30761061</pub-id>
</element-citation>
</ref>
<ref id="B118-ijms-21-04391">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adams</surname>
<given-names>P.E.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>D.V.</given-names>
</name>
<name>
<surname>Hessl</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Brunberg</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Koldewyn</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Grigsby</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Psychological symptoms correlate with reduced hippocampal volume in fragile X premutation carriers</article-title>
<source/>Am. J. Med. Genet. Part B Neuropsychiatr. Genet.
          <year>2010</year>
<volume>153</volume>
<fpage>775</fpage>
<lpage>785</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.31046</pub-id>
</element-citation>
</ref>
<ref id="B119-ijms-21-04391">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giulivi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Napoli</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Halmai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Plasma metabolic profile delineates roles for neurodegeneration, pro-inflammatory damage and mitochondrial dysfunction in the FMR1 premutation</article-title>
<source/>Biochem. J.
          <year>2016</year>
<volume>473</volume>
<fpage>3871</fpage>
<lpage>3888</lpage>
<pub-id pub-id-type="doi">10.1042/BCJ20160585</pub-id>
<pub-id pub-id-type="pmid">27555610</pub-id>
</element-citation>
</ref>
<ref id="B120-ijms-21-04391">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alvarez-Mora</surname>
<given-names>M.I.</given-names>
</name>
<name>
<surname>Rodriguez-Revenga</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Madrigal</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Guitart-Mampel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Garrabou</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Milà</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Impaired Mitochondrial Function and Dynamics in the Pathogenesis of FXTAS</article-title>
<source/>Mol. Neurobiol.
          <year>2017</year>
<volume>54</volume>
<fpage>6896</fpage>
<lpage>6902</lpage>
<pub-id pub-id-type="doi">10.1007/s12035-016-0194-7</pub-id>
<pub-id pub-id-type="pmid">27771901</pub-id>
</element-citation>
</ref>
<ref id="B121-ijms-21-04391">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Todd</surname>
<given-names>P.K.</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Krans</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sellier</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Frazer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Renoux</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Scaglione</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Basrur</surname>
<given-names>V.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CGG Repeat-Associated Translation Mediates Neurodegeneration in Fragile X Tremor Ataxia Syndrome</article-title>
<source/>Neuron
          <year>2013</year>
<volume>78</volume>
<fpage>440</fpage>
<lpage>455</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2013.03.026</pub-id>
<pub-id pub-id-type="pmid">23602499</pub-id>
</element-citation>
</ref>
<ref id="B122-ijms-21-04391">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Gibbens</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Doty</surname>
<given-names>N.S.</given-names>
</name>
<name>
<surname>Gomes-Pereira</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Huguet</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Stone</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Margolis</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Markowski</surname>
<given-names>T.W.</given-names>
</name>
<name>
<surname>Ingram</surname>
<given-names>M.A.C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Non-ATG–initiated translation directed by microsatellite expansions</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2011</year>
<volume>108</volume>
<fpage>260</fpage>
<lpage>265</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1013343108</pub-id>
<pub-id pub-id-type="pmid">21173221</pub-id>
</element-citation>
</ref>
<ref id="B123-ijms-21-04391">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bañez-Coronel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ayhan</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tarabochia</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Zu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Perez</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Tusi</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Pletnikova</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Borchelt</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Margolis</surname>
<given-names>R.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>RAN Translation in Huntington Disease</article-title>
<source/>Neuron
          <year>2015</year>
<volume>88</volume>
<fpage>667</fpage>
<lpage>677</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2015.10.038</pub-id>
<pub-id pub-id-type="pmid">26590344</pub-id>
</element-citation>
</ref>
<ref id="B124-ijms-21-04391">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cleary</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Ranum</surname>
<given-names>L.P.W.</given-names>
</name>
</person-group>
<article-title>New developments in RAN translation: Insights from multiple diseases</article-title>
<source/>Curr. Opin. Genet. Dev.
          <year>2017</year>
<volume>44</volume>
<fpage>125</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="doi">10.1016/j.gde.2017.03.006</pub-id>
<pub-id pub-id-type="pmid">28365506</pub-id>
</element-citation>
</ref>
<ref id="B125-ijms-21-04391">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cleary</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Pattamatta</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ranum</surname>
<given-names>L.P.W.</given-names>
</name>
</person-group>
<article-title>Repeat-associated non-ATG (RAN) translation</article-title>
<source/>J. Biol. Chem.
          <year>2018</year>
<volume>293</volume>
<fpage>16127</fpage>
<lpage>16141</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.R118.003237</pub-id>
<pub-id pub-id-type="pmid">30213863</pub-id>
</element-citation>
</ref>
<ref id="B126-ijms-21-04391">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sellier</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Buijsen</surname>
<given-names>R.A.M.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Natla</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tropel</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gaucherot</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jacobs</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Meziane</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Vincent</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Translation of Expanded CGG Repeats into FMRpolyG Is Pathogenic and May Contribute to Fragile X Tremor Ataxia Syndrome</article-title>
<source/>Neuron
          <year>2017</year>
<volume>93</volume>
<fpage>331</fpage>
<lpage>347</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2016.12.016</pub-id>
<pub-id pub-id-type="pmid">28065649</pub-id>
</element-citation>
</ref>
<ref id="B127-ijms-21-04391">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glineburg</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Todd</surname>
<given-names>P.K.</given-names>
</name>
<name>
<surname>Charlet-Berguerand</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sellier</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Repeat-associated non-AUG (RAN) translation and other molecular mechanisms in Fragile X Tremor Ataxia Syndrome</article-title>
<source/>Brain Res.
          <year>2018</year>
<volume>1693</volume>
<fpage>43</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2018.02.006</pub-id>
<pub-id pub-id-type="pmid">29453961</pub-id>
</element-citation>
</ref>
<ref id="B128-ijms-21-04391">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sellier</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Freyermuth</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tabet</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tran</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ruffenach</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Alunni</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Moine</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Thibault</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Page</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sequestration of DROSHA and DGCR8 by Expanded CGG RNA Repeats Alters MicroRNA Processing in Fragile X-Associated Tremor/Ataxia Syndrome</article-title>
<source/>Cell Rep.
          <year>2013</year>
<volume>3</volume>
<fpage>869</fpage>
<lpage>880</lpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2013.02.004</pub-id>
<pub-id pub-id-type="pmid">23478018</pub-id>
</element-citation>
</ref>
<ref id="B129-ijms-21-04391">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greco</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Chudley</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Del Bigio</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Jacquemont</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers</article-title>
<source/>Brain
          <year>2002</year>
<volume>125</volume>
<fpage>1760</fpage>
<lpage>1771</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awf184</pub-id>
<pub-id pub-id-type="pmid">12135967</pub-id>
</element-citation>
</ref>
<ref id="B130-ijms-21-04391">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Garcia-Arocena</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Khandjian</surname>
<given-names>E.W.</given-names>
</name>
<name>
<surname>Greco</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>Intranuclear inclusions in neural cells with premutation alleles in fragile X associated tremor/ataxia syndrome</article-title>
<source/>J. Med. Genet.
          <year>2004</year>
<volume>41</volume>
<fpage>e43</fpage>
<pub-id pub-id-type="doi">10.1136/jmg.2003.012518</pub-id>
<pub-id pub-id-type="pmid">15060119</pub-id>
</element-citation>
</ref>
<ref id="B131-ijms-21-04391">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iwahashi</surname>
<given-names>C.K.</given-names>
</name>
<name>
<surname>Yasui</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>An</surname>
<given-names>H.-J.</given-names>
</name>
<name>
<surname>Greco</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Nannen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Babineau</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lebrilla</surname>
<given-names>C.B.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>Protein composition of the intranuclear inclusions of FXTAS</article-title>
<source/>Brain
          <year>2005</year>
<volume>129</volume>
<fpage>256</fpage>
<lpage>271</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awh650</pub-id>
<pub-id pub-id-type="pmid">16246864</pub-id>
</element-citation>
</ref>
<ref id="B132-ijms-21-04391">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Herren</surname>
<given-names>A.W.</given-names>
</name>
<name>
<surname>Espinal</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Randol</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>McLaughlin</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Martinez-Cerdeño</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Pessah</surname>
<given-names>I.N.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>Composition of the Intranuclear Inclusions of Fragile X-associated Tremor/Ataxia Syndrome</article-title>
<source/>Acta Neuropathol. Commun.
          <year>2019</year>
<volume>7</volume>
<fpage>143</fpage>
<pub-id pub-id-type="doi">10.1186/s40478-019-0796-1</pub-id>
<pub-id pub-id-type="pmid">31481131</pub-id>
</element-citation>
</ref>
<ref id="B133-ijms-21-04391">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loomis</surname>
<given-names>E.W.</given-names>
</name>
<name>
<surname>Sanz</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Chédin</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>Transcription-Associated R-Loop Formation across the Human FMR1 CGG-Repeat Region</article-title>
<source/>PLoS Genet.
          <year>2014</year>
<volume>10</volume>
<elocation-id>e1004294</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1004294</pub-id>
<pub-id pub-id-type="pmid">24743386</pub-id>
</element-citation>
</ref>
<ref id="B134-ijms-21-04391">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roy</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lieber</surname>
<given-names>M.R.</given-names>
</name>
</person-group>
<article-title>G Clustering Is Important for the Initiation of Transcription-Induced R-Loops In Vitro, whereas High G Density without Clustering Is Sufficient Thereafter</article-title>
<source/>Mol. Cell. Biol.
          <year>2009</year>
<volume>29</volume>
<fpage>3124</fpage>
<lpage>3133</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.00139-09</pub-id>
<pub-id pub-id-type="pmid">19307304</pub-id>
</element-citation>
</ref>
<ref id="B135-ijms-21-04391">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belotserkovskii</surname>
<given-names>B.P.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tornaletti</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Krasilnikova</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Mirkin</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Hanawalt</surname>
<given-names>P.C.</given-names>
</name>
</person-group>
<article-title>Mechanisms and implications of transcription blockage by guanine-rich DNA sequences</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2010</year>
<volume>107</volume>
<fpage>12816</fpage>
<lpage>12821</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1007580107</pub-id>
<pub-id pub-id-type="pmid">20616059</pub-id>
</element-citation>
</ref>
<ref id="B136-ijms-21-04391">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Usdin</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>House</surname>
<given-names>N.C.M.</given-names>
</name>
<name>
<surname>Freudenreich</surname>
<given-names>C.H.</given-names>
</name>
</person-group>
<article-title>Repeat instability during DNA repair: Insights from model systems</article-title>
<source/>Crit. Rev. Biochem. Mol. Biol.
          <year>2015</year>
<volume>50</volume>
<fpage>142</fpage>
<lpage>167</lpage>
<pub-id pub-id-type="doi">10.3109/10409238.2014.999192</pub-id>
<pub-id pub-id-type="pmid">25608779</pub-id>
</element-citation>
</ref>
<ref id="B137-ijms-21-04391">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barzilai</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>DNA damage, neuronal and glial cell death and neurodegeneration</article-title>
<source/>Apoptosis
          <year>2010</year>
<volume>15</volume>
<fpage>1371</fpage>
<lpage>1381</lpage>
<pub-id pub-id-type="doi">10.1007/s10495-010-0501-0</pub-id>
<pub-id pub-id-type="pmid">20437103</pub-id>
</element-citation>
</ref>
<ref id="B138-ijms-21-04391">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaplan</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hulsizer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Berman</surname>
<given-names>R.F.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Pessah</surname>
<given-names>I.N.</given-names>
</name>
</person-group>
<article-title>Early mitochondrial abnormalities in hippocampal neurons cultured from Fmr1 pre-mutation mouse model</article-title>
<source/>J. Neurochem.
          <year>2012</year>
<volume>123</volume>
<fpage>613</fpage>
<lpage>621</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2012.07936.x</pub-id>
<pub-id pub-id-type="pmid">22924671</pub-id>
</element-citation>
</ref>
<ref id="B139-ijms-21-04391">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ross-Inta</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Omanska-Klusek</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Barrow</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Garcia-Arocena</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Iwahashi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Giulivi</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Evidence of mitochondrial dysfunction in fragile X-associated tremor/ataxia syndrome</article-title>
<source/>Biochem. J.
          <year>2010</year>
<volume>429</volume>
<fpage>545</fpage>
<lpage>552</lpage>
<pub-id pub-id-type="doi">10.1042/BJ20091960</pub-id>
<pub-id pub-id-type="pmid">20513237</pub-id>
</element-citation>
</ref>
<ref id="B140-ijms-21-04391">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Napoli</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ross-Inta</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Omanska-Klusek</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Barrow</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Iwahashi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Garcia-Arocena</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sakaguchi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Altered zinc transport disrupts mitochondrial protein processing/import in fragile X-associated tremor/ataxia syndrome</article-title>
<source/>Hum. Mol. Genet.
          <year>2011</year>
<volume>20</volume>
<fpage>3079</fpage>
<lpage>3092</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddr211</pub-id>
<pub-id pub-id-type="pmid">21558427</pub-id>
</element-citation>
</ref>
<ref id="B141-ijms-21-04391">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Napoli</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Giulivi</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Altered Redox Mitochondrial Biology in the Neurodegenerative Disorder Fragile X-Tremor/Ataxia Syndrome: Use of Antioxidants in Precision Medicine</article-title>
<source/>Mol. Med.
          <year>2016</year>
<volume>22</volume>
<fpage>548</fpage>
<lpage>559</lpage>
<pub-id pub-id-type="doi">10.2119/molmed.2016.00122</pub-id>
<pub-id pub-id-type="pmid">27385396</pub-id>
</element-citation>
</ref>
<ref id="B142-ijms-21-04391">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>The fragile-X premutation: A maturing perspective</article-title>
<source/>Am. J. Hum. Genet.
          <year>2004</year>
<volume>74</volume>
<fpage>805</fpage>
<lpage>816</lpage>
<pub-id pub-id-type="doi">10.1086/386296</pub-id>
<pub-id pub-id-type="pmid">15052536</pub-id>
</element-citation>
</ref>
<ref id="B143-ijms-21-04391">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salcedo-Arellano</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Dufour</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>McLennan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Martinez-Cerdeno</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Fragile X syndrome and associated disorders: Clinical aspects and pathology</article-title>
<source/>Neurobiol. Dis.
          <year>2020</year>
<volume>136</volume>
<fpage>104740</fpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2020.104740</pub-id>
<pub-id pub-id-type="pmid">31927143</pub-id>
</element-citation>
</ref>
<ref id="B144-ijms-21-04391">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greco</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Soontrapornchai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wirojanan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gould</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Testicular and Pituitary Inclusion Formation in Fragile X Associated Tremor/Ataxia Syndrome</article-title>
<source/>J. Urol.
          <year>2007</year>
<volume>177</volume>
<fpage>1434</fpage>
<lpage>1437</lpage>
<pub-id pub-id-type="doi">10.1016/j.juro.2006.11.097</pub-id>
<pub-id pub-id-type="pmid">17382748</pub-id>
</element-citation>
</ref>
<ref id="B145-ijms-21-04391">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Iwahashi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>FMR1 RNA within the Intranuclear Inclusions of Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS)</article-title>
<source/>RNA Biol.
          <year>2004</year>
<volume>1</volume>
<fpage>103</fpage>
<lpage>105</lpage>
<pub-id pub-id-type="doi">10.4161/rna.1.2.1035</pub-id>
<pub-id pub-id-type="pmid">17179750</pub-id>
</element-citation>
</ref>
<ref id="B146-ijms-21-04391">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ariza</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hartvigsen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Snell</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dill</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Judd</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Martínez-Cerdeño</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Iron accumulation and dysregulation in the putamen in fragile X-associated tremor/ataxia syndrome</article-title>
<source/>Mov. Disord.
          <year>2017</year>
<volume>32</volume>
<fpage>585</fpage>
<lpage>591</lpage>
<pub-id pub-id-type="doi">10.1002/mds.26902</pub-id>
<pub-id pub-id-type="pmid">28233916</pub-id>
</element-citation>
</ref>
<ref id="B147-ijms-21-04391">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ariza</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Steward</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rueckert</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Widdison</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Coffman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Afjei</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Noctor</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Martínez-Cerdeño</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Dysregulated iron metabolism in the choroid plexus in fragile X-associated tremor/ataxia syndrome</article-title>
<source/>Brain Res.
          <year>2015</year>
<volume>1598</volume>
<fpage>88</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2014.11.058</pub-id>
<pub-id pub-id-type="pmid">25498860</pub-id>
</element-citation>
</ref>
<ref id="B148-ijms-21-04391">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rogers</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ariza</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Monterrubio</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Martínez-Cerdeño</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Cerebellar Mild Iron Accumulation in a Subset of FMR1 Premutation Carriers with FXTAS</article-title>
<source/>Cerebellum
          <year>2016</year>
<volume>15</volume>
<fpage>641</fpage>
<lpage>644</lpage>
<pub-id pub-id-type="doi">10.1007/s12311-016-0798-5</pub-id>
<pub-id pub-id-type="pmid">27259564</pub-id>
</element-citation>
</ref>
<ref id="B149-ijms-21-04391">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cunningham</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Martínez Cerdeño</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Navarro Porras</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Prakash</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Angelastro</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Willemsen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Pessah</surname>
<given-names>I.N.</given-names>
</name>
<name>
<surname>Berman</surname>
<given-names>R.F.</given-names>
</name>
<name>
<surname>Noctor</surname>
<given-names>S.C.</given-names>
</name>
</person-group>
<article-title>Premutation CGG-repeat expansion of the Fmr1 gene impairs mouse neocortical development</article-title>
<source/>Hum. Mol. Genet.
          <year>2010</year>
<volume>20</volume>
<fpage>64</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddq432</pub-id>
<pub-id pub-id-type="pmid">20935171</pub-id>
</element-citation>
</ref>
<ref id="B150-ijms-21-04391">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martínez Cerdeño</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Amina</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lechpammer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ariza</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Noctor</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Microglial cell activation and senescence are characteristic of the pathology FXTAS</article-title>
<source/>Mov. Disord.
          <year>2018</year>
<volume>33</volume>
<fpage>1887</fpage>
<lpage>1894</lpage>
<pub-id pub-id-type="doi">10.1002/mds.27553</pub-id>
<pub-id pub-id-type="pmid">30537011</pub-id>
</element-citation>
</ref>
<ref id="B151-ijms-21-04391">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salcedo-Arellano</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Wolf-Ochoa</surname>
<given-names>M.W.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Amina</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lechpammer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Martínez-Cerdeño</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Parkinsonism versus concomitant Parkinson’s disease in Fragile X-associated Tremor/Ataxia Syndrome</article-title>
<source/>Mov. Disord. Clin. Pract.
          <year>2020</year>
<volume>7</volume>
<fpage>413</fpage>
<lpage>418</lpage>
<pub-id pub-id-type="doi">10.1002/mdc3.12942</pub-id>
<pub-id pub-id-type="pmid">32373658</pub-id>
</element-citation>
</ref>
<ref id="B152-ijms-21-04391">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aydin</surname>
<given-names>E.Y.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Protic</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Martínez-Cerdeño</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>H.-T.</given-names>
</name>
<name>
<surname>Perlman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Rapidly Progressing Neurocognitive Disorder in a Male with FXTAS and Alzheimer’s Disease</article-title>
<source/>Clin. Interv. Aging
          <year>2020</year>
<volume>15</volume>
<fpage>285</fpage>
<lpage>292</lpage>
<pub-id pub-id-type="doi">10.2147/CIA.S240314</pub-id>
<pub-id pub-id-type="pmid">32161452</pub-id>
</element-citation>
</ref>
<ref id="B153-ijms-21-04391">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Pablo-Fernandez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Doherty</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Holton</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Revesz</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Djamshidian</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Limousin</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bhatia</surname>
<given-names>K.P.</given-names>
</name>
<name>
<surname>Warner</surname>
<given-names>T.T.</given-names>
</name>
<name>
<surname>Lees</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Concomitant fragile X-associated tremor ataxia syndrome and Parkinson’s disease: A clinicopathological report of two cases</article-title>
<source/>J. Neurol. Neurosurg. Psychiatry
          <year>2015</year>
<volume>86</volume>
<fpage>934</fpage>
<lpage>936</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp-2014-309460</pub-id>
<pub-id pub-id-type="pmid">25476004</pub-id>
</element-citation>
</ref>
<ref id="B154-ijms-21-04391">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loesch</surname>
<given-names>D.Z.</given-names>
</name>
<name>
<surname>Litewka</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Brotchie</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Huggins</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Magnetic resonance imaging study in older fragile X premutation male carriers</article-title>
<source/>Ann. Neurol.
          <year>2005</year>
<volume>58</volume>
<fpage>326</fpage>
<lpage>330</lpage>
<pub-id pub-id-type="doi">10.1002/ana.20542</pub-id>
<pub-id pub-id-type="pmid">16049924</pub-id>
</element-citation>
</ref>
<ref id="B155-ijms-21-04391">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Birch</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Anheim</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jønch</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Pintado</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>O’Keefe</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Trollor</surname>
<given-names>J.N.</given-names>
</name>
<name>
<surname>Stebbins</surname>
<given-names>G.T.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Fahn</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Emerging topics in FXTAS</article-title>
<source/>J. Neurodev. Disord.
          <year>2014</year>
<volume>6</volume>
<fpage>31</fpage>
<pub-id pub-id-type="doi">10.1186/1866-1955-6-31</pub-id>
<pub-id pub-id-type="pmid">25642984</pub-id>
</element-citation>
</ref>
<ref id="B156-ijms-21-04391">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Abrams</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Coffey</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Greco</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gane</surname>
<given-names>L.W.</given-names>
</name>
<name>
<surname>Grigsby</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bourgeois</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Finucane</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Jacquemont</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Fragile X-associated tremor/ataxia syndrome: Clinical features, genetics, and testing guidelines</article-title>
<source/>Mov. Disord.
          <year>2007</year>
<volume>22</volume>
<fpage>2018</fpage>
<lpage>2030</lpage>
<pub-id pub-id-type="doi">10.1002/mds.21493</pub-id>
<pub-id pub-id-type="pmid">17618523</pub-id>
</element-citation>
</ref>
<ref id="B157-ijms-21-04391">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robertson</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>McAsey</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>O’Keefe</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Fragile X-associated tremor/ataxia syndrome: Phenotypic comparisons with other movement disorders</article-title>
<source/>Clin. Neuropsychol.
          <year>2016</year>
<volume>30</volume>
<fpage>849</fpage>
<lpage>900</lpage>
<pub-id pub-id-type="doi">10.1080/13854046.2016.1202239</pub-id>
<pub-id pub-id-type="pmid">27414076</pub-id>
</element-citation>
</ref>
<ref id="B158-ijms-21-04391">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polussa</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Molecular Advances Leading to Treatment Implications for Fragile X Premutation Carriers</article-title>
<source/>Brain Disord. Ther.
          <year>2014</year>
<volume>3</volume>
<fpage>1</fpage>
<lpage>14</lpage>
</element-citation>
</ref>
<ref id="B159-ijms-21-04391">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Kotermanski</surname>
<given-names>S.E.</given-names>
</name>
</person-group>
<article-title>Mechanism of action of memantine</article-title>
<source/>Curr. Opin. Pharmacol.
          <year>2006</year>
<volume>6</volume>
<fpage>61</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="doi">10.1016/j.coph.2005.09.007</pub-id>
<pub-id pub-id-type="pmid">16368266</pub-id>
</element-citation>
</ref>
<ref id="B160-ijms-21-04391">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seritan</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>D.V.</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bourgeois</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cogswell</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Grigsby</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Memantine for Fragile X–Associated Tremor/Ataxia Syndrome</article-title>
<source/>J. Clin. Psychiatry
          <year>2014</year>
<volume>75</volume>
<fpage>264</fpage>
<lpage>271</lpage>
<pub-id pub-id-type="doi">10.4088/JCP.13m08546</pub-id>
<pub-id pub-id-type="pmid">24345444</pub-id>
</element-citation>
</ref>
<ref id="B161-ijms-21-04391">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>J.-C.</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>Y.-Q.</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Seritan</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Moghaddam</surname>
<given-names>S.T.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Olichney</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Memantine Effects on Verbal Memory in Fragile X-associated Tremor/Ataxia Syndrome (FXTAS): A Double-Blind Brain Potential Study</article-title>
<source/>Neuropsychopharmacology
          <year>2014</year>
<volume>39</volume>
<fpage>2760</fpage>
<lpage>2768</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2014.122</pub-id>
<pub-id pub-id-type="pmid">24871547</pub-id>
</element-citation>
</ref>
<ref id="B162-ijms-21-04391">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>J.-C.</given-names>
</name>
<name>
<surname>Rodriguez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Royston</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>Y.-Q.</given-names>
</name>
<name>
<surname>Avar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Brill</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Grigsby</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Olichney</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Memantine Improves Attentional Processes in Fragile X-Associated Tremor/Ataxia Syndrome: Electrophysiological Evidence from a Randomized Controlled Trial</article-title>
<source/>Sci. Rep.
          <year>2016</year>
<volume>6</volume>
<fpage>21719</fpage>
<pub-id pub-id-type="doi">10.1038/srep21719</pub-id>
<pub-id pub-id-type="pmid">26898832</pub-id>
</element-citation>
</ref>
<ref id="B163-ijms-21-04391">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Napoli</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Trivedi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Carrillo</surname>
<given-names>N.R.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Rogawski</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Giulivi</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Allopregnanolone Treatment Improves Plasma Metabolomic Profile Associated with GABA Metabolism in Fragile X-Associated Tremor/Ataxia Syndrome: A Pilot Study</article-title>
<source/>Mol. Neurobiol.
          <year>2019</year>
<volume>56</volume>
<fpage>3702</fpage>
<lpage>3713</lpage>
<pub-id pub-id-type="doi">10.1007/s12035-018-1330-3</pub-id>
<pub-id pub-id-type="pmid">30187385</pub-id>
</element-citation>
</ref>
<ref id="B164-ijms-21-04391">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Trivedi</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Carrillo</surname>
<given-names>N.R.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Giulivi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>S.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Open-Label Allopregnanolone Treatment of Men with Fragile X-Associated Tremor/Ataxia Syndrome</article-title>
<source/>Neurotherapeutics
          <year>2017</year>
<volume>14</volume>
<fpage>1073</fpage>
<lpage>1083</lpage>
<pub-id pub-id-type="doi">10.1007/s13311-017-0555-6</pub-id>
<pub-id pub-id-type="pmid">28707277</pub-id>
</element-citation>
</ref>
<ref id="B165-ijms-21-04391">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Secades</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Frontera</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>CDP-Choline: Pharmacological and clinical review</article-title>
<source/>Methods Find. Exp. Clin. Pharmacol.
          <year>1995</year>
<volume>17</volume>
<fpage>1</fpage>
<lpage>54</lpage>
</element-citation>
</ref>
<ref id="B166-ijms-21-04391">
<label>166.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>E.E.</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>McAsey</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ouyang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>O’Keefe</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Open-label pilot clinical trial of citicoline for fragile X-associated tremor/ataxia syndrome (FXTAS)</article-title>
<source/>PLoS ONE
          <year>2020</year>
<volume>15</volume>
<elocation-id>e0225191</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0225191</pub-id>
<pub-id pub-id-type="pmid">32053612</pub-id>
</element-citation>
</ref>
<ref id="B167-ijms-21-04391">
<label>167.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verma</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mishra</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Mishra</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Charlet-Berguerand</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Curcumin Regulates the r(CGG)exp RNA Hairpin Structure and Ameliorate Defects in Fragile X-Associated Tremor Ataxia Syndrome</article-title>
<source/>Front. Neurosci.
          <year>2020</year>
<volume>14</volume>
<fpage>295</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2020.00295</pub-id>
<pub-id pub-id-type="pmid">32317919</pub-id>
</element-citation>
</ref>
<ref id="B168-ijms-21-04391">
<label>168.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verma</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mishra</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Jain</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Piperine Modulates Protein Mediated Toxicity in Fragile X-Associated Tremor/Ataxia Syndrome through Interacting Expanded CGG Repeat (r(CGG)exp) RNA</article-title>
<source/>ACS Chem. Neurosci.
          <year>2019</year>
<volume>10</volume>
<fpage>3778</fpage>
<lpage>3788</lpage>
<pub-id pub-id-type="doi">10.1021/acschemneuro.9b00282</pub-id>
<pub-id pub-id-type="pmid">31264835</pub-id>
</element-citation>
</ref>
<ref id="B169-ijms-21-04391">
<label>169.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qurashi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ray</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Chemical screen reveals small molecules suppressing fragile X premutation rCGG repeat-mediated neurodegeneration in Drosophila</article-title>
<source/>Hum. Mol. Genet.
          <year>2012</year>
<volume>21</volume>
<fpage>2068</fpage>
<lpage>2075</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/dds024</pub-id>
<pub-id pub-id-type="pmid">22298836</pub-id>
</element-citation>
</ref>
<ref id="B170-ijms-21-04391">
<label>170.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seritan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bourgeois</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cogswell</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Grigsby</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Memantine for Fragile X-Associated Tremor/Ataxia Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial</article-title>
<source/>J. Clin. Psychiatry
          <year>2013</year>
<volume>75</volume>
<fpage>264</fpage>
<pub-id pub-id-type="doi">10.4088/JCP.13m08546</pub-id>
</element-citation>
</ref>
<ref id="B171-ijms-21-04391">
<label>171.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trivedi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Carrillo</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Allopregnanolone improves neuropsychiatric symptoms in elderly men with Fragile X-associated tremor/ataxia syndrome (FXTAS): Results from an open label study</article-title>
<source/>Neurology
          <year>2019</year>
<volume>92</volume>
</element-citation>
</ref>
<ref id="B172-ijms-21-04391">
<label>172.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sayeed</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Parvez</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wali</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Siemen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>D.G.</given-names>
</name>
</person-group>
<article-title>Direct inhibition of the mitochondrial permeability transition pore: A possible mechanism for better neuroprotective effects of allopregnanolone over progesterone</article-title>
<source/>Brain Res.
          <year>2009</year>
<volume>1263</volume>
<fpage>165</fpage>
<lpage>173</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2009.01.045</pub-id>
<pub-id pub-id-type="pmid">19368823</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="ijms-21-04391-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Clinical manifestations of the fragile X premutation and fragile X-associated tremor/ataxia syndrome (FXTAS) overtime. * Clinical manifestations which are more prevalent in females with the fragile X premutation than males. (Adapted from Leehey et al. 2007; Greco et al. 2006) [<xref ref-type="bibr" rid="B42-ijms-21-04391">42</xref>,<xref ref-type="bibr" rid="B75-ijms-21-04391">75</xref>].</p>
</caption>
<graphic xlink:href="ijms-21-04391-g001"></graphic>
</fig>
<fig id="ijms-21-04391-f002" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>Repeat associated non-AUG (RAN) translation in FXTAS. RAN translation leads to the production of RAN products depending on the location where the initiation of translation occurs. Initiation (black triangles) occurring in the +0 reading frame leads to the production of FMRpolyR (green squares), +1 to FMRpolyG (brown squares), and +2, within the CGG-repeat region, to the production of FMRpolyA (yellow squares). (Adapted from Glineburg et al. 2018) [<xref ref-type="bibr" rid="B127-ijms-21-04391">127</xref>].</p>
</caption>
<graphic xlink:href="ijms-21-04391-g002"></graphic>
</fig>
<fig id="ijms-21-04391-f003" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<p><italic>FMR1</italic> RNA induced protein sequestration. The expanded CGG-repeat region in the <italic>FMR1</italic> free mRNA can form higher-order structures that can sequester proteins which results in a deficiency within the cell from those proteins. The CGG-repeat region is directly bound by repeat binding proteins such as heterogeneous nuclear ribonucleoproteins A2/B1 (hnRNP A2/B1), DiGeorge syndrome critical region 8 (DGCR8) protein, and Pur-alpha ((Purα) protein. The CGG-repeat region can also indirectly sequester other proteins through the interaction with the directly bound proteins. Proteins that can be indirectly sequestered include Drosha and heterochromatin protein 1 (HP1). (Adapted from Hagerman and Hagerman 2016 and Glineburg et al. 2018) [<xref ref-type="bibr" rid="B12-ijms-21-04391">12</xref>,<xref ref-type="bibr" rid="B127-ijms-21-04391">127</xref>].</p>
</caption>
<graphic xlink:href="ijms-21-04391-g003"></graphic>
</fig>
<fig id="ijms-21-04391-f004" orientation="portrait" position="float">
<label>Figure 4</label>
<caption>
<p>Neuroradiological criteria for the diagnosis of FXTAS. (<bold>A</bold>) T2-FLAIR: white matter lesions in the splenium of the corpus callosum, (<bold>B</bold>) T2-TSE: symmetrical white matter lesions in the middle cerebellar peduncles (MCP sign), (<bold>C</bold>) T2-FLAIR: cerebral white matter lesions and brain atrophy.</p>
</caption>
<graphic xlink:href="ijms-21-04391-g004"></graphic>
</fig>
<fig id="ijms-21-04391-f005" orientation="portrait" position="float">
<label>Figure 5</label>
<caption>
<p>New therapeutic approaches and associated molecular pathways. (<bold>A</bold>) Compounds such as curcumin and piperine have shown to selectively bind the CGG repeat hairpin structure, inhibiting sequestration of RNA and other proteins that are normally involved in cellular mechanisms such as splicing, microRNA processing, and RNA transportation. By inhibiting the sequestration of such proteins, the cell is no longer functionally deficient from them, improving splicing alterations and reducing ribonuclear inclusions formation. (<bold>B</bold>) Curcumin and piperine can also decrease the synthesis of toxic homopolymeric proteins such as FMRpolyG (brown squares) and FMRpolyA (yellow squares), therefore reducing neuronal toxic effects caused by them [<xref ref-type="bibr" rid="B167-ijms-21-04391">167</xref>,<xref ref-type="bibr" rid="B168-ijms-21-04391">168</xref>]. (Adapted from Hagerman and Hagerman 2016; Glineburg et al. 2018) [<xref ref-type="bibr" rid="B12-ijms-21-04391">12</xref>,<xref ref-type="bibr" rid="B127-ijms-21-04391">127</xref>].</p>
</caption>
<graphic xlink:href="ijms-21-04391-g005"></graphic>
</fig>
<table-wrap id="ijms-21-04391-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-21-04391-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>Diagnostic criteria and categories for FXTAS. Adapted from Hall et al. 2014 [<xref ref-type="bibr" rid="B155-ijms-21-04391">155</xref>].</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Diagnostic Criteria</th>
</tr>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Molecular</th>
<th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Required</th>
<th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>FMR1</italic> Mutation *</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Clinical</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Major</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Intention tremor</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cerebellar gait ataxia</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Minor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Parkinsonism</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Neuropathy</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Memory and executive function deficits</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Neuroradiological</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Major</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">White matter lesions in the middle cerebellar peduncles (MCP sign) or brainstem</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Minor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">White matter lesions in the splenium of the corpus callosum</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cerebral white matter lesions</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Moderate–severe brain atrophy</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Neuropathological</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Major</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Ubiquitin-positive intranuclear inclusions</td>
</tr>
<tr>
<td align="center" colspan="3" rowspan="1" style="border-bottom:solid thin" valign="middle">Diagnostic categories</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Definite</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1 clinical major<break></break>AND<break></break>1 neuroradiological major OR<break></break>1 neuropathological major</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Probable</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2 clinical major<break></break>OR<break></break>1 clinical minor + 1 radiological minor</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Possible</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1 clinical major + 1 clinical minor</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p><italic>* FMR1</italic> mutation includes premutation, gray zone and FM with mosaicism.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="ijms-21-04391-t002" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-21-04391-t002_Table 2</object-id>
<label>Table 2</label>
<caption>
<p>New therapeutic approaches and associated molecular pathways.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Medication/Compound</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Molecular Mechanism</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Clinical Trial Phases Completed</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Curcumin</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decreases RANT and FMRpolyG production, reducing its accumulation.</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Preclinical</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B167-ijms-21-04391">167</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Selectively binds CGG RNA repeats potentially reducing RNA binding proteins sequestration and reducing CGG repeats-induced cell toxicity.</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cytidine 5′diphospho-choline<break></break>(Citicoline)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibition of phospholipase A<sub>2</sub> (PLA<sub>2</sub>) leading to suppression of CGG repeats-induced cell toxicity.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Phase 2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B166-ijms-21-04391">166</xref>,<xref ref-type="bibr" rid="B169-ijms-21-04391">169</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Memantine</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Noncompetitive antagonist of N-methyl-d-aspartate (NMDA) proposed to normalize premutation associated abnormal neuronal response to glutamate.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Phase 2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B161-ijms-21-04391">161</xref>,<xref ref-type="bibr" rid="B170-ijms-21-04391">170</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Piperine</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Selectively binds CGG RNA repeats potentially reducing RNA binding proteins sequestration and reducing CGG repeats-induced cell toxicity.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Preclinical</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B168-ijms-21-04391">168</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">Allopregnanolone</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Positive allosteric modulator of GABA receptors.</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">Phase 2</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B163-ijms-21-04391">163</xref>,<xref ref-type="bibr" rid="B164-ijms-21-04391">164</xref>,<xref ref-type="bibr" rid="B171-ijms-21-04391">171</xref>,<xref ref-type="bibr" rid="B172-ijms-21-04391">172</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reduction of caspase-3 protein expression leading to reduced apoptosis.</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibition of mitochondrial permeability transition pore which is implicated in the intrinsic pathway of apoptosis.</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>